StudyFinder
Search Results
Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
Search all categories
641 Study Matches
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC)
Charles Theuer, MD, PhD - clinicaltrials@traconpharma.com
Poklepovic, Andrew, S
NCT04480502
HM20023448
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Histologically confirmed locally advanced or metastatic undifferentiated pleomorphic sarcoma (UPS) or grade ≥ 2 myxofibrosarcoma (MFS)
• Documented progression following systemic chemotherapy
• At least one measurable lesion
• Eastern Cooperative Oncology Group performance status of 0 or 1
• Adequate hematologic and organ function
Exclusion Criteria:
• More than two prior lines of chemotherapy for UPS/MFS
• Prior immune checkpoint inhibitor or immunomodulatory therapy
• Active autoimmune disease that has required systemic treatment
• Major surgery within 4 weeks of dosing of investigational agent
• Active additional malignancy
• Pericardial effusion, pleural effusion, or ascites
• Central nervous system metastases and/or carcinomatous meningitis
• Active hepatitis or cirrhosis
• Interstitial lung disease
• Unwilling to apply highly effective contraception during the study
• Other concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, contraindicate patient participation in the clinical study
Biological: Envafolimab, Drug: Ipilimumab
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
sarcoma
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 30 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Cleveland Clinic Cleveland, Ohio | |
| Columbia University New York, New York | |
| Dana Farber Cancer Institute Boston, Massachusetts | |
| Duke University Durham, North Carolina | |
| H. Lee Moffitt Cancer Center Tampa, Florida | |
| Huntsman Cancer Institute Salt Lake City, Utah | |
| Johns Hopkins University Columbia, Maryland | |
| Massachusetts General Hospital Boston, Massachusetts | |
| Mayo Clinic Rochester Rochester, Minnesota | |
| Mayo Clinic, Jacksonville Jacksonville, Florida | |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Memorial Sloan Kettering Cancer Center New York, New York | |
| Northwestern University Chicago, Illinois | |
| Ohio State University Columbus, Ohio | |
| Royal Marsden London, | |
| Sarcoma Oncology Research Center Santa Monica, California | |
| Seattle Cancer Care Alliance Seattle, Washington | |
| Stanford University Palo Alto, California | |
| Thomas Jefferson University (Sidney Kimmel Cancer Center) Philadelphia, Pennsylvania | |
| University Hospitals Cleveland, Ohio | |
| University of Arizona Tucson, Arizona | |
| University of California, Los Angeles Los Angeles, California | |
| University of Colorado Denver, Colorado | |
| University of Miami Miami, Florida | |
| University of Michigan Ann Arbor, Michigan | |
| University of Pennsylvania Philadelphia, Pennsylvania | |
| University of Pittsburgh Pittsburgh, Pennsylvania | |
| Vanderbilt University Nashville, Tennessee | |
| Virginia Commonwealth University Richmond, Virginia | |
| Washington University in St. Louis St Louis, Missouri |
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial (CLASP II TR)
Edwards TMTT Clinical Affairs - TMTT_Clinical@edwards.com
Gertz, Zachary
NCT04097145
HM20023593
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Eighteen (18) years of age or older
* Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR.
* Severe or greater tricuspid regurgitation
* New York Heart Association (NYHA) Class II-IVa or heart failure hospitalization in the prior 12 months
* Patient is at an intermediate or greater estimated risk of mortality with tricuspid valve surgery as determined by the cardiac surgeon with concurrence by the local Heart Team
* Patient is able and willing to give informed consent, follow protocol procedures, and comply with follow-up visit requirements
Exclusion Criteria:
* Tricuspid valve anatomy not evaluable by TTE or TEE
* Tricuspid valve anatomy precludes proper device deployment and function
* Patient with refractory heart failure requiring, advanced intervention (i.e. patient has or will need left ventricular assist device, or transplantation) (ACC/AHA Stage D heart failure)
* Presence of trans-tricuspid pacemaker or defibrillator leads which meet one of the following:
• Would prevent proper TR reduction due to interaction of the lead with the leaflets
• Were implanted in the RV within the last 90 days prior to the point of enrollment * Primary non-degenerative tricuspid disease * Previous tricuspid valve repair or replacement that would interfere with placement of PASCAL * Clinically significant, untreated coronary artery disease requiring revascularization, unstable angina, evidence of acute coronary syndrome, recent myocardial infarction * Significant intra-cardiac mass, thrombus, or vegetation per echo core lab assessment * Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 90 days * Recent Stroke * Active gastrointestinal (GI) bleeding * Presence of infiltrative cardiomyopathy or valvulopathy (including carcinoid, amyloidosis, sarcoidosis, hemochromatosis) or significant congenital heart disease, including but not limited to atrial septal defect, RV dysplasia, and arrhythmogenic RV * Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365 days), or any planned percutaneous cardiac procedure within the next 90 days * Any of the following cardiovascular procedures:
• Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days prior to the point of enrollment
• Carotid surgery within 30 days prior to the point of enrollment
• Direct current cardioversion within the last 30 days prior to the point of enrollment
• Leadless RV pacemaker implant within the last 30 days prior to the point of enrollment
• Cardiac surgery within 90 days prior to the point of enrollment * Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation * Known history of untreated severe symptomatic carotid stenosis or asymptomatic carotid stenosis * Active endocarditis within the last 90 days or infection requiring antibiotic therapy within the last 14 days * Patient is oxygen-dependent or requires continuous home oxygen * Pregnant, breastfeeding, or planning pregnancy within the next 12 months (365 days) * Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator * Patient is currently participating in another investigational biologic, drug, or device clinical study * Patient has other medical, social, or psychological conditions that preclude appropriate consent and follow-up, or the patient is under guardianship * Any patient considered to be vulnerable
DEVICE: Edwards PASCAL System, DRUG: Optimal Medical Therapy, DEVICE: Edwards PASCAL System, DEVICE: Edwards PASCAL System
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 79 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Ascension St. Vincent Heart Center Cardiovascular Research Institute Indianapolis, Indiana | |
| Banner University Medical Center Phoenix Phoenix, Arizona | |
| Baylor College of Medicine St. Luke's Medical Center Houston, Texas | |
| Baylor Scott & White - The Heart Hospital - Plano Plano, Texas | |
| Carilion Medical Center Roanoke, Virginia | |
| Cedars Sinai Medical Center Los Angeles, California | |
| Columbia University Irving Medical Center/NYPH New York, New York | |
| Cooper Health Systems Camden, New Jersey | |
| Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire | |
| Emory University Hospital Midtown / Emory University - St. Joseph's Hospital Atlanta, Georgia | |
| Erlanger Health System Chattanooga, Tennessee | |
| Fairview Health Services Saint Paul, Minnesota | |
| HCA Houston Healthcare Medical Center Houston, Texas | |
| Hamilton Health Services Hamilton, Ontario | |
| Henry Ford Hospital Detroit, Michigan | |
| Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval Québec, Quebec | |
| Integris Baptist Medical Center Oklahoma City, Oklahoma | |
| Intermountain Medical Center Murray, Utah | |
| Johns Hopkins Baltimore, Maryland | |
| Kaiser Permanente San Francisco San Francisco, California | |
| Lankenau Heart Institute Wynnewood, Pennsylvania | |
| Lenox Hill Hospital, Northwell Health /Northshore University Hospital Manhasset New York, New York | |
| Massachusetts General Hospital Boston, Massachusetts | |
| Mayo Clinic Rochester, Minnesota | |
| Medical Center of the Rockies Loveland, Colorado | |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Medical University of South Carolina Charleston, South Carolina | |
| Montefiore Medical Center / Arts Pavilion / Hutchinson Metro Center Clinic / Weiler Hospital / Moses Hospital The Bronx, New York | |
| Morristown Medical Center Morristown, New Jersey | |
| Mount Sinai Medical Center Miami Beach, Florida | |
| NCH Healthcare System Naples, Florida | |
| Northwestern University Chicago, Illinois | |
| Ochsner Medical Center New Orleans, Louisiana | |
| Oklahoma Cardiovascular Research Group Oklahoma City, Oklahoma | |
| Oklahoma Heart Institute at Hillcrest Medical Center Tulsa, Oklahoma | |
| Oregon Health & Science University Portland, Oregon | |
| Penn State Hershey Hershey, Pennsylvania | |
| Pennsylvania Presbyterian Medical Center / Hospital of the University of Pennsylvania Philadelphia, Pennsylvania | |
| Piedmont Healthcare, Inc. Atlanta, Georgia | |
| Pinnacle Health Cardiovascular Institute/UPMC Pinnacle Wormleysburg, Pennsylvania | |
| Providence St. Patrick Hospital Missoula, Montana | |
| Rochester General Hospital Rochester, New York | |
| Rutgers Robert Wood Johnson Medical School New Brunswick, New Jersey | |
| SCPMG - Kaiser San Diego La Jolla, California | |
| Saint Luke's Hospital of Kansas City Kansas City, Missouri | |
| Sanford Medical Center Fargo Fargo, North Dakota | |
| Sarasota Memorial Health Care System Sarasota, Florida | |
| St. Francis Hospital Roslyn, New York | |
| St. George Regional Hospital St. George, Utah | |
| St. Joseph Hospital Bethpage, New York | |
| St. Mary's of Ascension Research Saginaw, Michigan | |
| St. Michael's Hospital Toronto, Ontario | |
| St. Paul's Hospital Iloilo City, | |
| Stanford University Palo Alto, California | |
| State University Of New York at Buffalo Buffalo, New York | |
| Sunnybrook Health Sciences Centre Toronto, Ontario | |
| Swedish Medical Center Englewood, Colorado | |
| Tallahassee Research Institute Tallahassee, Florida | |
| The Cardiac and Vascular Institute Research Foundation Gainesville, Florida | |
| The Christ Hospital Cincinnati, Ohio | |
| The Ohio State University Columbus, Ohio | |
| The University of Texas Health Science Center at Houston Houston, Texas | |
| TriHealth-Bethesda North Hospital Cincinnati, Ohio | |
| Tucson Medical Center HealthCare Tucson, Arizona | |
| UCLA Medical Center Los Angeles, California | |
| UTHealth/Memorial Hermann Hospital Houston, Texas | |
| University of California, Irvine Orange, California | |
| University of California, San Francisco San Francisco, California | |
| University of Iowa Hospitals & Clinics Iowa City, Iowa | |
| University of Michigan Ann Arbor, Michigan | |
| University of North Carolina Chapel Hill, North Carolina | |
| University of Ottawa Heart Institute Ottawa, Ontario | |
| University of Virginia Health System Charlottesville, Virginia | |
| Vanderbilt University Medical Center Nashville, Tennessee | |
| Virginia Commonwealth University Richmond, Virginia | |
| Virginia Mason Medical Center Seattle, Washington | |
| Washington University School of Medicine St Louis, Missouri | |
| Weill Cornell Medicine New York, New York | |
| William Beaumont Hospital - Royal Oak Royal Oak, Michigan |
Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment (CRT-DRIVE)
Claudia M Amatruda, PhD - amatruda@xspline.com
NCT05327062
Show full eligibility criteria
Hide eligibility criteria
Eligible subjects shall meet all following criteria:
• Appropriately signed and dated informed consent.
• Age ≥18 years at time of consent.
• CRT indication according to the 2021 ESC guidelines on cardiac pacing and CRT (class I and IIA indication in patients with LBBB QRS morphology) or to 2017 AHA/ACC/HFSA guidelines (COR I).
• Sinus rhythm
• QRS duration ≥130 ms
• Left bundle branch block
• Left ventricular ejection fraction ≤35%
• Symptomatic heart failure NYHA class ≥ II
• Documented stable medical treatment for at least 6 months
• No cardiovascular intervention during the last 6 month Exclusion Criteria are:
• History of persistent or permanent atrial fibrillation
• Previous pacemaker or ICD implantation
• Indication to pacing due to bradycardia
• Patients considered for His bundle pacing or cardiac conduction pacing
• Patients with unstable angina
• Subject experienced a recent myocardial infarction, within 40 days prior to enrollment
• Subject underwent coronary artery bypass graft or valve surgery, within 90 days prior to enrollment
• Subject is post heart transplantation, or is actively listed on the transplantation list, or has reasonable probability (per investigator's discretion) of undergoing transplantation in the next year
• Subject is implanted with a left ventricular assist device
• Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure
• Subject has severe aortic stenosis (with a valve area of <1.0 cm2 or significant valve disease expected to be operated within study period)
• Subject has congenital heart disease
• Subject has a mechanical right-sided heart valve
• Subject has a life expectancy of less than one year in the opinion of the investigator
• Pregnant or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control
• Subject is enrolled in one or more concurrent studies that would confound the results of this study
• Patients who have contraindications to CT scanning.
• Patients with chronic kidney diseases and estimated glomerular filtration rate (eGMR) calculated based on CKD-EPI 2009 < 40 ml/min/1.73m2
• Appropriately signed and dated informed consent.
• Age ≥18 years at time of consent.
• CRT indication according to the 2021 ESC guidelines on cardiac pacing and CRT (class I and IIA indication in patients with LBBB QRS morphology) or to 2017 AHA/ACC/HFSA guidelines (COR I).
• Sinus rhythm
• QRS duration ≥130 ms
• Left bundle branch block
• Left ventricular ejection fraction ≤35%
• Symptomatic heart failure NYHA class ≥ II
• Documented stable medical treatment for at least 6 months
• No cardiovascular intervention during the last 6 month Exclusion Criteria are:
• History of persistent or permanent atrial fibrillation
• Previous pacemaker or ICD implantation
• Indication to pacing due to bradycardia
• Patients considered for His bundle pacing or cardiac conduction pacing
• Patients with unstable angina
• Subject experienced a recent myocardial infarction, within 40 days prior to enrollment
• Subject underwent coronary artery bypass graft or valve surgery, within 90 days prior to enrollment
• Subject is post heart transplantation, or is actively listed on the transplantation list, or has reasonable probability (per investigator's discretion) of undergoing transplantation in the next year
• Subject is implanted with a left ventricular assist device
• Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure
• Subject has severe aortic stenosis (with a valve area of <1.0 cm2 or significant valve disease expected to be operated within study period)
• Subject has congenital heart disease
• Subject has a mechanical right-sided heart valve
• Subject has a life expectancy of less than one year in the opinion of the investigator
• Pregnant or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth control
• Subject is enrolled in one or more concurrent studies that would confound the results of this study
• Patients who have contraindications to CT scanning.
• Patients with chronic kidney diseases and estimated glomerular filtration rate (eGMR) calculated based on CKD-EPI 2009 < 40 ml/min/1.73m2
Device: CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment
Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block
Non-invasive activation mapping, Coronary Sinus
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 16 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Amsterdam University Medical Center Amsterdam, | Reinoud Knops - (r.e.knops@amsterdamumc.nl) |
| Duke University Hospital Durham, North Carolina | Daniel Friedman - (daniel.friedman@duke.edu) |
| General Hospital of Bolzano Bolzano, | Rainer Oberhollenzer - (rainer.oberhollenzer@sabes.it) |
| Istituto Cardiocentro Ticino Lugano, Tessin | Angelo Auricchio - (angelo.auricchio@eoc.ch) |
| King's College Hospital London, | Aldo Rinaldi - (aldo.rinaldi@kcl.ac.uk) |
| Maastricht University Medical Center Maastricht, | Kevin Vernooy - (kevin.vernooy@mumc.nl) |
| Massachusetts General Hospital Boston, Massachusetts | Jag Singh - (JSINGH@mgh.harvard.edu) |
| Ordensklinikum Linz Elisabethinen Hospital Linz, | Helmut Puererfellner - (helmut.puererfellner@ordensklinikum.at) |
| Policlinico Casilino Rome, | Leonardo Calò - (leonardo.calo@icloud.com) |
| Queen Elizabeth Hospital South Woodville, | Francisco Leyva - (cardiologists@hotmail.com) |
| Rush University Medical Center Chicago, Illinois | Parikshit S Sharma - (parikshit_S_Sharma@rush.edu) |
| Semmelweis University Budapest, | Bela Merkely - (merkely.bela@gmail.com) |
| The University of Chicago Medicine Chicago, Illinois | Gaurav Upadhyay - (gupadhyay@medicine.bsd.uchicago.edu) |
| UKSH Universitätsklinikum Schleswig-Holstein Kiel, | Thomas Demming - (thomas.demming@uksh.de) |
| Univeristat de Barcelona Barcelona, | Lluis Mont - (lmont@clinic.cat) |
| Virginia Commonwealth University School of Medicine Richmond, Virginia | Kenneth Ellenbogen - (kenneth.ellenbogen@vcuhealth.org) |
Quality of Pediatric Resuscitation in a Multicenter Collaborative (pediRES-Q)
Vinay Nadkarni, MD, MS - nadkarni@chop.edu
NCT02708134
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patient received chest compressions for at least 1 minute
* Patient between gestational age ≥37 weeks and 18 years of age
Exclusion Criteria:
* Patient on veno-arterial extracorporeal membrane oxygenation (ECMO) therapy at beginning of CPR event Cardiac Arrest, Cardiopulmonary Arrest
Chest compressions, Cardiopulmonary Resuscitation, Pediatric
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 61 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Aichi Children's Health and Medical Center Ōbu, | |
| Akron Children's Akron, Ohio | |
| Albany Medical Center Albany, New York | |
| Alberta Children's Calgary, | |
| All Children's Hospital St. Petersburg, Florida | |
| BC Children's Vancouver, British Columbia | |
| Boston Children's Boston, Massachusetts | |
| Cedars-Sinai Medical Center Los Angeles, California | |
| Children's Colorado Aurora, Colorado | |
| Children's Healthcare of Atlanta (CHOA) Atlanta, Georgia | |
| Children's Hospital of Philadelphia Philadelphia, Pennsylvania | Vinay Nadkarni, MD, MS - (nadkarni@chop.edu) |
| Children's Hospital of Richmond at VCU Richmond, Virginia | |
| Chldren's Hospital of Orange County Orange, California | |
| Cincinnati Children's Hospital Medical Center Cincinnati, Ohio | |
| Cohen Children's Medical Center New Hyde Park, New York | |
| Dartmouth Hitchcock Medical Center Lebanon, New Hampshire | |
| Dell Children's Medical Center Austin, Texas | |
| Erasmus MC - Sophia Children's Rotterdam, | |
| Great Ormond Street Hospital London, | |
| Gregorio Marañón General University Hospital Madrid, | |
| IRCCS Ospedale Pediatrico Bambino Gesu Rome, | |
| Instituto Roosevelt Bogotá, | |
| KK Women's & Children's Hospital Singapore, | |
| Kaiser Permanente Portland, Oregon | |
| Kentucky Children's Hospital Lexington, Kentucky | |
| King Chulalongkorn University Bangkok, | |
| Kobe Children's Hospital (Hyogo Prefectural) Kobe, | |
| Lurie Children's (Children's Hospital of Chicago) Chicago, Illinois | |
| Massachusetts General Hospital Boston, Massachusetts | |
| Medical City Children's Hospital Dallas, Texas | |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Medical University of South Carolina Charleston, South Carolina | |
| Morgan Stanley Children's Hospital New York, New York | |
| Mount Sinai Kravis Children's Hospital New York, New York | |
| National Taiwan University Hospital Taipei, | |
| National University Hospital Singapore, | |
| Nationwide Children's Hospital Columbus, Ohio | |
| Nebraska Medical Center Omaha, Nebraska | |
| Nemours Children's Hospital Orlando, Florida | |
| Perth Children's Hospital Perth, Western Australia | |
| Queensland Children's Hospital South Brisbane, Queensland | |
| Rady Children's Hospital San Diego, California | |
| Riley Hospital for Children Indianapolis, Indiana | |
| Sabara Hospital Infantil São Paulo, | |
| Seattle Children's Hospital Seattle, Washington | |
| Seoul National University Bundang Hospital Seongnam-si, Gyeonggi-do | |
| St. Louis Children's Hospital St Louis, Missouri | |
| Stanford University Palo Alto, California | |
| Starship Children's Hospital Grafton, Auckland | |
| Stollery Children's Hospital Edmonton, | |
| Stony Brook University Hospital Stony Brook, New York | |
| The Children's Hospital at Westmead Westmead, New South Wales | |
| The Children's Hospital of San Antonio San Antonio, Texas | |
| The Johns Hopkins Hospital Baltimore, Maryland | |
| Tokyo Metropolitan Children's Medical Center Tokyo, | |
| University of Chicago, Comer Children's Hospital Chicago, Illinois | |
| University of Iowa Stead Family Children's Hospital Iowa City, Iowa | |
| University of North Carolina Chapel Hill, North Carolina | |
| University of Texas Southwestern Dallas, Texas | |
| Upstate Golisano Children's Hospital Syracuse, New York | |
| Valley Children's Hospital Madera, California |
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Gwaltney, Lindsey - lbgwaltney@vcu.edu
Boomer, Laura, A
NCT05235165
HM20024392
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients must be \< 50 years at the time of enrollment.
* Patients must have =\< 4 nodules per lung consistent with or suspicious for metastases, with at least one of which being \>= 3 mm and all of which must be =\< 3 cm size.
* Note: Patient must have eligibility confirmed by rapid central imaging review.
* Lung nodules must be considered resectable by either open thoracotomy or thoracoscopic surgery. Determination of resectability is made by the institutional surgeon.
* Patients must have a histological diagnosis of osteosarcoma.
* Patients must have evidence of metastatic lung disease at the time of initial diagnosis, or at time of 1st recurrence following completion of therapy for initially localized disease.
* Patients with newly diagnosed disease must have completed successful gross tumor resection for their primary tumor or surgical local control of primary tumor must be planned to be performed simultaneously with thoracic surgery.
* Newly diagnosed patients must be receiving or recently completed (within 60 days) systemic therapy considered by the treating physician to be standard treatment for newly diagnosed osteosarcoma (eg, cisplatin-doxorubicin or ifosfamide-based drug regimens) at the time of enrollment on this study. Dose and drug modifications for toxicity do not exclude patients from participation.
* Patients at time of 1st recurrence must have completed systemic therapy for their initial primary tumor, considered by the treating physician to be standard treatment for newly diagnosed osteosarcoma (eg, cisplatin-doxorubicin or ifosfamide-based drug regimens) at the time of enrollment on this study. Dose and drug modifications for toxicity do not exclude patients from participation.
Exclusion Criteria:
* Patients with unresectable primary tumor.
* Patients with pulmonary metastatic lesions that would require anatomic resection (lobectomy or pneumonectomy) or lesions that are defined as "central" (i.e., central lesion involves or is proximal to segmental bronchi and peripheral is lesion distal to segmental bronchi).
* Patients with chest wall or mediastinal based metastatic lesions, or with significant pleural effusion.
* Patients with disease progression at either the primary or pulmonary metastatic site while on initial therapy. Note: Once the patient has been enrolled on the study, additional computed tomography (CT) scans are not anticipated prior to thoracic surgery. Note: Some variation in nodule size measurements over the course of pre-operative therapy is anticipated and does not qualify for exclusion unless deemed true disease progression by the primary treatment team.
* Patients with evidence of extrapulmonary metastatic disease.
* Patients who received therapeutic pulmonary surgery for lung metastasis prior to enrollment.
* All patients and/or their parents or legal guardians must sign a written informed consent.
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met. PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, OTHER: Questionnaire Administration, PROCEDURE: Thoracoscopy, PROCEDURE: Thoracotomy
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 232 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Albany Medical Center Albany, New York | |
| Alberta Children's Hospital Calgary, Alberta | |
| Alfred I duPont Hospital for Children Wilmington, Delaware | Site Public Contact - (Allison.bruce@nemours.org) |
| Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Ann M Wierman MD LTD Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Arkansas Children's Hospital Little Rock, Arkansas | |
| Arnold Palmer Hospital for Children Orlando, Florida | Site Public Contact - (Jennifer.spinelli@orlandohealth.com) |
| BI-LO Charities Children's Cancer Center Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Banner Children's at Desert Mesa, Arizona | |
| Banner University Medical Center - Tucson Tucson, Arizona | Site Public Contact - (UACC-IIT@uacc.arizona.edu) |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas | Site Public Contact - (burton@bcm.edu) |
| Beacon Kalamazoo Kalamazoo, Michigan | |
| Beacon Kalamazoo Cancer Center Kalamazoo, Michigan | |
| Blank Children's Hospital Des Moines, Iowa | Site Public Contact - (samantha.mallory@unitypoint.org) |
| Bronson Battle Creek Battle Creek, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Bronson Methodist Hospital Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| C S Mott Children's Hospital Ann Arbor, Michigan | |
| Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan | Site Public Contact - (connie.szczepanek@crcwm.org) |
| Cardinal Glennon Children's Medical Center St Louis, Missouri | |
| Carilion Children's Roanoke, Virginia | Site Public Contact - (wpmccarty@carilionclinic.org) |
| Carson Tahoe Regional Medical Center Carson City, Nevada | Site Public Contact - (research@sncrf.org) |
| Cedars Sinai Medical Center Los Angeles, California | |
| Centre Hospitalier Universitaire Sainte-Justine Montreal, Quebec | Site Public Contact - (yvan.samson@umontreal.ca) |
| Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Sherbrooke, Quebec | Site Public Contact - (crcinformation.chus@ssss.gouv.qc.ca) |
| Children's Healthcare of Atlanta - Arthur M Blank Hospital Atlanta, Georgia | Site Public Contact - (Olivia.Floyd@choa.org) |
| Children's Hospital Colorado Aurora, Colorado | Site Public Contact - (josh.b.gordon@nsmtp.kp.org) |
| Children's Hospital Los Angeles Los Angeles, California | |
| Children's Hospital Medical Center Of Akron Akron, Ohio | |
| Children's Hospital New Orleans New Orleans, Louisiana | |
| Children's Hospital and Medical Center of Omaha Omaha, Nebraska | |
| Children's Hospital at Montefiore The Bronx, New York | Site Public Contact - (aaraiza@montefiore.org) |
| Children's Hospital of Alabama Birmingham, Alabama | Site Public Contact - (oncologyresearch@peds.uab.edu) |
| Children's Hospital of Michigan Detroit, Michigan | Site Public Contact - (helpdesk@childrensoncologygroup.org) |
| Children's Hospital of Orange County Orange, California | Site Public Contact - (oncresearch@choc.org) |
| Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania | Site Public Contact - (jean.tersak@chp.edu) |
| Children's Hospital of San Antonio San Antonio, Texas | Site Public Contact - (bridget.medina@christushealth.org) |
| Children's Hospital of Wisconsin Milwaukee, Wisconsin | Site Public Contact - (MACCCTO@mcw.edu) |
| Children's Hospital of the King's Daughters Norfolk, Virginia | Site Public Contact - (CCBDCresearch@chkd.org) |
| Children's Hospitals and Clinics of Minnesota - Minneapolis Minneapolis, Minnesota | Site Public Contact - (pauline.mitby@childrensmn.org) |
| Children's Mercy Hospitals and Clinics Kansas City, Missouri | Site Public Contact - (COGResearchGroup@cmh.edu) |
| Children's National Medical Center Washington D.C., District of Columbia | Site Public Contact - (OncCRC_OnCall@childrensnational.org) |
| Christchurch Hospital Christchurch, | |
| Cincinnati Children's Hospital Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@cchmc.org) |
| Cleveland Clinic Foundation Cleveland, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Comprehensive Cancer Centers of Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Central Valley Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Northwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Town Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Horizon Ridge Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Southeast Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Summerlin Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Connecticut Children's Medical Center Hartford, Connecticut | |
| Cook Children's Medical Center Fort Worth, Texas | Site Public Contact - (CookChildrensResearch@cookchildrens.org) |
| Corewell Health Children's Royal Oak, Michigan | |
| Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan | |
| Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Reed City Hospital Reed City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Dana-Farber Cancer Institute Boston, Massachusetts | |
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire | Site Public Contact - (cancer.research.nurse@dartmouth.edu) |
| Dayton Children's Hospital Dayton, Ohio | |
| Dell Children's Medical Center of Central Texas Austin, Texas | Site Public Contact - (TXAUS-DL-SFCHemonc.research@ascension.org) |
| Driscoll Children's Hospital Corpus Christi, Texas | Site Public Contact - (Crystal.DeLosSantos@dchstx.org) |
| Duke University Medical Center Durham, North Carolina | |
| East Carolina University Greenville, North Carolina | Site Public Contact - (eubankss@ecu.edu) |
| East Tennessee Childrens Hospital Knoxville, Tennessee | |
| Eastern Maine Medical Center Bangor, Maine | |
| El Paso Children's Hospital El Paso, Texas | Site Public Contact - (ranjan.bista@ttuhsc.edu) |
| Geisinger Medical Center Danville, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Golisano Children's Hospital of Southwest Florida Fort Myers, Florida | Site Public Contact - (molly.arnstrom@leehealth.org) |
| HIMA San Pablo Oncologic Hospital Caguas, | |
| Hackensack University Medical Center Hackensack, New Jersey | |
| Hope Cancer Care of Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Hope Cancer Care of Nevada-Pahrump Pahrump, Nevada | Site Public Contact - (research@sncrf.org) |
| IWK Health Centre Halifax, Nova Scotia | |
| Inova Fairfax Hospital Falls Church, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Johns Hopkins All Children's Hospital St. Petersburg, Florida | Site Public Contact - (Ashley.Repp@jhmi.edu) |
| Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland | Site Public Contact - (jhcccro@jhmi.edu) |
| Kaiser Permanente Downey Medical Center Downey, California | |
| Kaiser Permanente Los Angeles Medical Center Los Angeles, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Anaheim Anaheim, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Bellflower Bellflower, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Fontana Fontana, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Oakland Oakland, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-San Diego Zion San Diego, California | Site Public Contact - (clinical.trials@kp.org) |
| Kapiolani Medical Center for Women and Children Honolulu, Hawaii | |
| King Faisal Specialist Hospital and Research Centre Riyadh, | |
| Kingman Regional Medical Center Kingman, Arizona | Site Public Contact - (research@sncrf.org) |
| Las Vegas Cancer Center-Henderson Henderson, Nevada | |
| Las Vegas Cancer Center-Medical Center Las Vegas, Nevada | |
| Las Vegas Urology - Cathedral Rock Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Green Valley Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Pebble Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Pecos Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Smoke Ranch Las Vegas, Nevada | Site Public Contact - (research@smcrf.org) |
| Las Vegas Urology - Sunset Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York | Site Public Contact - (CancerTrials@nyulangone.org) |
| Legacy Emanuel Children's Hospital Portland, Oregon | |
| Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Loma Linda University Medical Center Loma Linda, California | |
| Loyola University Medical Center Maywood, Illinois | |
| Lucile Packard Children's Hospital Stanford University Palo Alto, California | Site Public Contact - (ccto-office@stanford.edu) |
| Lurie Children's Hospital-Chicago Chicago, Illinois | |
| M D Anderson Cancer Center Houston, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| Madigan Army Medical Center Tacoma, Washington | Site Public Contact - (melissa.a.forouhar.mil@health.mil) |
| Maimonides Medical Center Brooklyn, New York | |
| Maine Children's Cancer Program Scarborough, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| Marshfield Medical Center-Marshfield Marshfield, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Mary Bridge Children's Hospital and Health Center Tacoma, Washington | Site Public Contact - (research@multicare.org) |
| Massachusetts General Hospital Cancer Center Boston, Massachusetts | |
| Mayo Clinic in Rochester Rochester, Minnesota | |
| Medical City Dallas Hospital Dallas, Texas | |
| Medical University of South Carolina Charleston, South Carolina | Site Public Contact - (hcc-clinical-trials@musc.edu) |
| Memorial Sloan Kettering Cancer Center New York, New York | |
| Mercy Hospital Saint Louis St Louis, Missouri | |
| Methodist Children's Hospital of South Texas San Antonio, Texas | Site Public Contact - (Vinod.GidvaniDiaz@hcahealthcare.com) |
| Michigan State University East Lansing, Michigan | |
| Miller Children's and Women's Hospital Long Beach Long Beach, California | |
| Mission Hospital Asheville, North Carolina | Site Public Contact - (NCDV.ResearchRegulatory@HCAHealthcare.com) |
| Montefiore Medical Center - Moses Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Montefiore Medical Center-Einstein Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Montefiore Medical Center-Weiler Hospital The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Morristown Medical Center Morristown, New Jersey | |
| Mount Sinai Hospital New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Munson Medical Center Traverse City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, New York | Site Public Contact - (cancerclinicaltrials@cumc.columbia.edu) |
| Nationwide Children's Hospital Columbus, Ohio | Site Public Contact - (Melinda.Triplet@nationwidechildrens.org) |
| Nemours Children's Clinic-Jacksonville Jacksonville, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| Nemours Children's Hospital Orlando, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| New York Medical College Valhalla, New York | |
| Nicklaus Children's Hospital Miami, Florida | |
| North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Yakima, Washington | Site Public Contact - (Memorial-ClinicalTrials@yvmh.org) |
| Northern Nevada Radiation Oncology Reno, Nevada | |
| Northwestern Medicine Central DuPage Hospital Winfield, Illinois | Site Public Contact - (Claudine.Gamster@CadenceHealth.org) |
| Norton Children's Hospital Louisville, Kentucky | Site Public Contact - (CancerResource@nortonhealthcare.org) |
| Ochsner Medical Center Jefferson New Orleans, Louisiana | Site Public Contact - (Elisemarie.curry@ochsner.org) |
| Oncology Las Vegas - Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Oncology Las Vegas - Tenaya Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at Charleston Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at Fort Apache Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at MountainView Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at Seven Hills Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Oregon Health and Science University Portland, Oregon | Site Public Contact - (trials@ohsu.edu) |
| Overlake Medical Center Bellevue, Washington | |
| PCR Oncology Arroyo Grande, California | Site Public Contact - (research@sncrf.org) |
| Penn State Children's Hospital Hershey, Pennsylvania | |
| Perth Children's Hospital Perth, Western Australia | |
| Phoenix Childrens Hospital Phoenix, Arizona | |
| Presbyterian Hospital Albuquerque, New Mexico | Site Public Contact - (wburman@phs.org) |
| Primary Children's Hospital Salt Lake City, Utah | |
| Prisma Health Richland Hospital Columbia, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio | Site Public Contact - (PCIOncResearch@promedica.org) |
| Providence Alaska Medical Center Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Providence Sacred Heart Medical Center and Children's Hospital Spokane, Washington | Site Public Contact - (HopeBeginsHere@providence.org) |
| Radiation Oncology Associates Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Radiation Oncology Centers of Nevada Central Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Radiation Oncology Centers of Nevada Southeast Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Rady Children's Hospital - San Diego San Diego, California | |
| Rainbow Babies and Childrens Hospital Cleveland, Ohio | |
| Renown Regional Medical Center Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Rhode Island Hospital Providence, Rhode Island | |
| Riley Hospital for Children Indianapolis, Indiana | |
| Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center Denver, Colorado | Site Public Contact - (PSGResearchSharedMailbox@HCAHealthcare.com) |
| Royal Children's Hospital Parkville, Victoria | |
| Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital New Brunswick, New Jersey | |
| Saint Christopher's Hospital for Children Philadelphia, Pennsylvania | |
| Saint Joseph's Hospital/Children's Hospital-Tampa Tampa, Florida | Site Public Contact - (jennifer.manns@baycare.org) |
| Saint Joseph's Regional Medical Center Paterson, New Jersey | Site Public Contact - (HallL@sjhmc.org) |
| Saint Jude Children's Research Hospital Memphis, Tennessee | Site Public Contact - (referralinfo@stjude.org) |
| Saint Jude Midwest Affiliate Peoria, Illinois | |
| Saint Luke's Cancer Institute - Boise Boise, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Mary's Regional Medical Center Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Saint Peter's University Hospital New Brunswick, New Jersey | Site Public Contact - (kcovert@saintpetersuh.com) |
| Sanford Broadway Medical Center Fargo, North Dakota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota | Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org) |
| Seattle Children's Hospital Seattle, Washington | |
| Sinai Hospital of Baltimore Baltimore, Maryland | |
| Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Starship Children's Hospital Grafton, Auckland | |
| State University of New York Upstate Medical University Syracuse, New York | |
| Stony Brook University Medical Center Stony Brook, New York | |
| Summerlin Hospital Medical Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Sunrise Hospital and Medical Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Tampa General Hospital Tampa, Florida | Site Public Contact - (syapchanyk@tgh.org) |
| Texas Tech University Health Sciences Center-Amarillo Amarillo, Texas | |
| The Children's Hospital at TriStar Centennial Nashville, Tennessee | |
| The Children's Hospital at Westmead Westmead, New South Wales | |
| The Montreal Children's Hospital of the MUHC Montreal, Quebec | |
| The Steven and Alexandra Cohen Children's Medical Center of New York New Hyde Park, New York | |
| Trinity Health Grand Rapids Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Trinity Health Muskegon Hospital Muskegon, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| UCSF Medical Center-Mission Bay San Francisco, California | Site Public Contact - (cancertrials@ucsf.edu) |
| UF Health Cancer Institute - Gainesville Gainesville, Florida | |
| UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas | Site Public Contact - (canceranswerline@UTSouthwestern.edu) |
| University Medical Center of Southern Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| University of Alberta Hospital Edmonton, Alberta | Site Public Contact - (pedsoncologyresearch@ahs.ca) |
| University of California Davis Comprehensive Cancer Center Sacramento, California | |
| University of Chicago Comprehensive Cancer Center Chicago, Illinois | Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu) |
| University of Illinois Chicago, Illinois | |
| University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa | |
| University of Kentucky/Markey Cancer Center Lexington, Kentucky | |
| University of Maryland/Greenebaum Cancer Center Baltimore, Maryland | |
| University of Michigan Health - West Wyoming, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| University of Michigan Rogel Cancer Center Ann Arbor, Michigan | Site Public Contact - (CancerAnswerLine@med.umich.edu) |
| University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota | |
| University of Mississippi Medical Center Jackson, Mississippi | |
| University of Missouri Children's Hospital Columbia, Missouri | Site Public Contact - (snwq62@health.missouri.edu) |
| University of Nebraska Medical Center Omaha, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Texas Health Science Center at San Antonio San Antonio, Texas | Site Public Contact - (phoresearchoffice@uthscsa.edu) |
| University of Vermont and State Agricultural College Burlington, Vermont | |
| University of Virginia Cancer Center Charlottesville, Virginia | Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu) |
| University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| Urology Specialists of Nevada - Central Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Green Valley Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Northwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Southwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| VCU Massey Cancer Center at Stony Point Richmond, Virginia | Site Public Contact - (ctoclinops@vcu.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Valley Children's Hospital Madera, California | Site Public Contact - (Research@valleychildrens.org) |
| Valley Medical Center Renton, Washington | Site Public Contact - (research@valleymed.org) |
| Vanderbilt University/Ingram Cancer Center Nashville, Tennessee | |
| Wake Forest University Health Sciences Winston-Salem, North Carolina | |
| Walter Reed National Military Medical Center Bethesda, Maryland | |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| West Michigan Cancer Center Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| West Virginia University Healthcare Morgantown, West Virginia | Site Public Contact - (cancertrialsinfo@hsc.wvu.edu) |
| Westchester Medical Center Valhalla, New York | Site Public Contact - (ctsucontact@westat.com) |
| Yale University New Haven, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors (i-RECORd)
Marco Carini, Prof. - carini@unifi.it
NCT05363657
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Radiological diagnosis of renal tumor susceptible to active treatment or AS/WW.
• Age ?18 years
• Informed consent signed
Exclusion Criteria:
• Patient refuse to participate in clinical research.
• Urothelial renal carcinoma.
Procedure: Partial Nephrectomy (PN), Procedure: Radical Nephrectomy (RN), Procedure: Ablation therapy (AT), Diagnostic Test: Active Surveillance (AS)
Kidney Cancer
Kidney cancer, Partial Nephrectomy, Radical Nephrectomy, Ablation Techniques, Active Surveillance, Recurrence Free Survival, Watchful Waiting
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 37 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AOUI Verona Verona, Vr | Alessandro Antonelli - (alessandro.antonelli@me.com) |
| Amsterdam University Medical Centers Amsterdam, | Axel Bex - (a.bex@nki.nl) |
| Azienda Ospedaliera Policlinico "G. Martino", Universit? di Messina. Messina, | Vincenzo Ficarra - (vficarra@unime.it) |
| Bristol Urological Institute Bristol, | Francis Keeley - (Francis.Keeley@nbt.nhs.uk) |
| Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital Firenze, | Andrea Mari - (andrea.mari@unifi.it) |
| Division of Urology, University of Genoa,Policlinico San Martino Hospital Genova, | Carlo Terrone - (carlo.terrone@med.uniupo.it) |
| European Health Center Otwock, | Lukasz Nyk - (ukinyk@poczta.fm) Hubert Kamecki - (hubert@kamecki.pl) |
| Fundaci? Puigvert Barcelona, | Joan Palou - (ipalou@fundacio-puigvert.es) |
| Guy's Hospital Great Maze Pond, | Ben Challacombe - (benchallacombe@doctors.org.uk) |
| Hospital Universitario Ram?n y Cajal, University of Alcal Madrid, | Vital Hevia - (vital.hevia.uro@gmail.com) |
| Humanitas Hospital Rozzano, | Nicolomaria Buffi - (nicolo.buffi@hunimed.eu) |
| Institute Oncology Veneto (IOV) Padova, | Angelo Porreca - (angeloporreca@gmail.com) |
| Institute of Urology, University of Southern California. Los Angeles, California | Giovanni E Cacciamani - (giovanni.cacciamani@med.usc.edu) |
| Istituto Nazionale dei Tumori Fondazione Senatore "G. Pascale" Napoli, | Sisto Perdona' - (s.perdona@istitutotumori.na.it) |
| Jikei University School of Medicine Minato-ku, Tokyo, | Shin Egawa - (s-egpro@jikei.ac.jp) |
| Loyola University Medical Center, Edward Hines VA Hospital Chicago, Illinois | Gopal Gupta - (GOGUPTA@lumc.edu) |
| Medical University of Vienna, Vienna General Hospital Vienna, | Shahkrokh F Shariat - (shahrokh.shariat@meduniwien.ac.at) |
| N.N. Blokhin National Medical Research Center of Oncology Moscow, | Vsevolod Matveev - (vsevolodmatveev@mail.ru) |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Warsaw, | Roman Sosnowski - (roman.sosnowski@gmail.com) |
| Ng Teng Fong General Hospital Singapore, | Vineet Gaauhaar - (vineetgaauhaar@gmail.com) |
| Onze Lieve Vrouw Hospital Leuven, | Geert De Naeyer - (geertdenaeyer@yahoo.com) |
| Policlinico Istituto Europeo di Oncologia (IEO) Milano, | Ottavio De Cobelli - (Ottavio.DeCobelli@ieo.it) |
| Policlinico Riuniti, Universit? di Foggia. Foggia, | Giuseppe Carrieri - (giuseppe.carrieri@unifg.it) Gian Maria Busetto - (gianmaria.busetto@unifg.it) |
| Policlinico S. Orsola Malpighi Bologna, | Riccardo Schiavina - (rschiavina@yahoo.it) |
| San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital Milano, | Umberto Capitanio - (umbertocapitanio@gmail.com) |
| Santa Casa da Miseric?rdia de Fortaleza Fortaleza, | Francisco Hidelbrando A Mota Filho - (fha.motafilho@gmail.com) |
| Stanford University Palo Alto, California | Benjamin I Chung - (bichung@stanford.edu) |
| Swedish Hospital Seattle, Washington | James Porter - (porter@swedishurology.com) |
| Universit? degli Studi di Torino, Ospedale S. Luigi Gonzaga. Torino, | Francesco Porpiglia - (porpiglia@libero.it) |
| Universit? degli studi di Torino, Ospedale Molinette Torino, | Paolo Gontero - (paolo.gontero@unito.it) |
| University Hospitals Leuven Leuven, | Maarten Albersen - (maarten.albersen@uzleuven.be) |
| University of Bruxelles Bruxelles, | Simone Albisinni - (albisinni.simone@gmail.com) |
| University of California San Diego, Moores Cancer Center San Diego, California | Ithaar Derweesh - (iderweesh@gmail.com) |
| University of Patras Patras, | Evangelos Liatsikos - (liatsikos@yahoo.com) |
| University of Pennsylvania Philadelphia, Pennsylvania | Philip Pierorazio - (Phillip.Pierorazio@pennmedicine.upenn.edu) |
| Urology, Andrology & Kidney Transplantation Unit, University of Bari Bari, | Pasquale Ditonno - (pasquale.ditonno@uniba.it) |
| VCU Health System Richmond, Virginia | Riccardo Autorino - (ricautor@gmail.com) |
Single-Session Intervention - Neurocognitive Functioning of Children/Adolescents - Neurofibromatosis (OPTIMAL-SSI)
Jewell, Andrea - Andrea.Jewell@vcuhealth.org
Rohan, Jennifer
NCT05377008
HM20024159
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Patients are eligible if they are English-speaking children and adolescents between the ages of 6 to 16 years diagnosed with NF who are currently followed by the Pediatric NF Clinic at VCU. Patients are eligible if they currently have a diagnosis of ADHD or do not have a diagnosis of ADHD.
• At least one parent/caregiver must be actively involved in the patient's care and able to complete study-related questionnaires at baseline, 3-, and 6-months; and the exit interview at 7-months. Parents are eligible if they if they are English-speaking adults 18+ years old and self-identify as the parent or guardian of the patient.
Exclusion Criteria:
• Presence of serious, chronic comorbid condition (asthma and ADHD are not exclusionary criteria), presence of serious cognitive/learning impairment (e.g., down syndrome, moderate to severe intellectual disability or developmental disability), temporary foster care or residential care placement with no known plans to remain with foster parent for at least one year, presence of serious ongoing psychiatric disorder that prevents patient or family member from accurately completing questionnaires, and/or family anticipates moving in the next 12 months.
• No subject will be excluded on the basis of gender or ethnicity.
Behavioral: OPTIMAL-SSI
Neurocognitive Deficit, Mental Health Impairment, Neurofibromatosis 1, Neoplasms
Neurofibromatosis, Neurocognitive, Intervention
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 2 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Children's Hospital of Richmond at Virginia Commonwealth University Richmond, Virginia | Jennifer Rohan, PhD - (jennifer.rohan@vcuhealth.org) Clara Ko, MS - (clara.ko@vcuhealth.org) |
| Virginia Commonwealth University Richmond, Virginia | Jewell, Andrea - (Andrea.Jewell@vcuhealth.org) |
Microeconomic Intervention to Reduce HIV Transmission in Economically Disadvantaged Transgender Women
Eric Benotsch, PhD - ebenotsch@vcu.edu
Benotsch, Eric, G
NCT04275310
HM20011245
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Transgender woman
• 18-45 years of age At least one of the following economic vulnerability factors: unemployment or underemployment [less than 20 hours/week], low income [less than the Medicaid poverty threshold], housing insecurity in the past year or food insecurity in the past year • Behavioral vulnerability to HIV transmission (reported at least one episode of unprotected sex in prior 6 months or at least one other behavioral HIV transmission risk factor in the past 6 months: [transactional sex, multiple sexual partners, 1-time sexual partner, sex under the influence of drugs or alcohol, sex with partner of unknown HIV status).
Exclusion Criteria:
• obvious signs of intoxication or cognitive impairment
• cannot speak English.
Behavioral: Microeconomic Intervention
Hiv, Transgenderism
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia |
Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon
ABBVIE CALL CENTER - abbvieclinicaltrials@abbvie.com
Chaudary, Nauman
NCT05069597
HM20025086
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Previous diagnosis of cystic fibrosis (CF) or chronic pancreatitis (CP).
• Previous diagnosis of exocrine pancreatic insufficiency (EPI) that is currently clinically controlled.
• Total Symptom Score (TSS) < 1.8 on Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) at Screening.
Exclusion Criteria:
• Malignancy involving the digestive tract in the last 5 years, or other significant disease or medical condition that may interfere with EPI symptom assessment.
Drug: CREON
Cystic Fibrosis, Chronic Pancreatitis
Cystic Fibrosis, Chronic Pancreatitis, Exocrine Pancreatic Insufficiency, Creon, Pancrelipase
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 22 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Albany Medical College-Pulmonary /ID# 250041 Albany, New York | |
| Asr, Llc /Id# 239566 Nampa, Idaho | |
| Atlantic Medical Research Group /ID# 239568 Margate, Florida | |
| Baylor College of Medicine Medical Center /ID# 233441 Houston, Texas | |
| Central FL Pulmonary Orlando /ID# 245863 Orlando, Florida | |
| Children's Hospital of Richmond at VCU /ID# 245988 Richmond, Virginia | |
| Cleveland Clinic Main Campus /ID# 245864 Cleveland, Ohio | |
| Dartmouth-Hitchcock Medical Center /ID# 231633 Lebanon, New Hampshire | |
| GI Pros /ID# 239486 Naples, Florida | |
| NYU Langone Health /ID# 233417 New York, New York | |
| Options Health Research, LLC /ID# 239535 Tulsa, Oklahoma | |
| The Curators of the University of Missouri /ID# 233331 Columbia, Missouri | |
| UH Cleveland Medical Center /ID# 246065 Cleveland, Ohio | |
| UMass Chan Medical School /ID# 230476 Worcester, Massachusetts | |
| Univ Texas HSC San Antonio /ID# 239060 San Antonio, Texas | |
| University of Cincinnati /ID# 229511 Cincinnati, Ohio | Site Coordinator |
| University of Florida - Archer /ID# 233411 Gainesville, Florida | |
| University of Miami, Miller School of Medicine /ID# 239415 Miami, Florida | |
| Valley Children's Hospital /ID# 231452 Madera, California | |
| Velocity Clinical Research /ID# 231076 Mobile, Alabama | Site Coordinator |
| Wake Forest Baptist Health /ID# 229537 Winston-Salem, North Carolina | |
| West Virginia University Hospitals /ID# 239593 Morgantown, West Virginia |
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)
Pascaline Clerc - clinical.contact@inventivapharma.com
Luketic, Velimir, A
NCT04849728
HM20024140
Show full eligibility criteria
Hide eligibility criteria
Prescreening Criteria:
• Diagnosed with NASH on prior liver biopsy
• Type 2 diabetes with high waist circumference or obesity or hepatic steatosis on ultrasound
• At least 3 of the components of metabolic syndrome
• Male or female, aged ≥18 years at the time of signing informed consent
• Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):
• Steatosis score ≥1
• Activity score: A3 or A4
• Fibrosis score: F2 or F3
• No qualitative change in dose for the drugs listed below:
• Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months
• Vitamin E (if at a dose ≥400 IU/day): for at least 6 months
• Statins: for at least 3 months
• No qualitative change in dose for all other chronically administered drugs for at least 3 months prior to Screening
• Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)
• Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation.
• Documented causes of chronic liver disease other than NASH
• Histologically documented liver cirrhosis (fibrosis stage F4)
• History or current diagnosis of hepatocellular carcinoma (HCC)
• History of or planned liver transplant
• Positive human immunodeficiency virus (HIV) serology
• ALT or AST >5 × ULN
• AST<0.6 ULN if the liver biopsy has to be performed in the scope of the study
• Abnormal synthetic liver function as defined by Screening central laboratory evaluation
• Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males
• Patient currently receiving any approved treatment for NASH or obesity
• Current or recent history (<5 years) of significant alcohol consumption
• Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD) administered for at least 2 weeks within 12 months prior to qualifying liver biopsy Glycaemia related:
• HbA1c >9% at Screening
• Diabetes mellitus other than type 2
• Current treatment with insulin
• Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy. Obesity related:
• Bariatric surgery: Restrictive procedures are allowed, if performed >6 months prior to the qualifying liver biopsy; malabsorptive procedures and procedures combining both restrictive and malabsorptive methods are not allowed within 5 years of the qualifying liver biopsy. Cardiovascular related:
• History of heart failure with reduced left ventricular ejection fraction (LVEF)
• Atrial fibrillation requiring anticoagulation
• Unstable heart failure
• Uncontrolled hypertension at Screening (values >160/100 mm Hg) General safety:
• Women currently breastfeeding
• Previous exposure to lanifibranor
• Participation in any clinical trial investigational medicinal product/device within 3 months from Screening or 5 half-lives from Screening, whichever is longer
• Concomitant treatment with PPAR-alpha agonists (fibrates)
• Diagnosed with NASH on prior liver biopsy
• Type 2 diabetes with high waist circumference or obesity or hepatic steatosis on ultrasound
• At least 3 of the components of metabolic syndrome
Inclusion Criteria:
• Male or female, aged ≥18 years at the time of signing informed consent
• Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):
• Steatosis score ≥1
• Activity score: A3 or A4
• Fibrosis score: F2 or F3
• No qualitative change in dose for the drugs listed below:
• Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months
• Vitamin E (if at a dose ≥400 IU/day): for at least 6 months
• Statins: for at least 3 months
• No qualitative change in dose for all other chronically administered drugs for at least 3 months prior to Screening
• Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)
• Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation.
Exclusion Criteria:
Liver-related:
• Documented causes of chronic liver disease other than NASH
• Histologically documented liver cirrhosis (fibrosis stage F4)
• History or current diagnosis of hepatocellular carcinoma (HCC)
• History of or planned liver transplant
• Positive human immunodeficiency virus (HIV) serology
• ALT or AST >5 × ULN
• AST<0.6 ULN if the liver biopsy has to be performed in the scope of the study
• Abnormal synthetic liver function as defined by Screening central laboratory evaluation
• Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males
• Patient currently receiving any approved treatment for NASH or obesity
• Current or recent history (<5 years) of significant alcohol consumption
• Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD) administered for at least 2 weeks within 12 months prior to qualifying liver biopsy Glycaemia related:
• HbA1c >9% at Screening
• Diabetes mellitus other than type 2
• Current treatment with insulin
• Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy. Obesity related:
• Bariatric surgery: Restrictive procedures are allowed, if performed >6 months prior to the qualifying liver biopsy; malabsorptive procedures and procedures combining both restrictive and malabsorptive methods are not allowed within 5 years of the qualifying liver biopsy. Cardiovascular related:
• History of heart failure with reduced left ventricular ejection fraction (LVEF)
• Atrial fibrillation requiring anticoagulation
• Unstable heart failure
• Uncontrolled hypertension at Screening (values >160/100 mm Hg) General safety:
• Women currently breastfeeding
• Previous exposure to lanifibranor
• Participation in any clinical trial investigational medicinal product/device within 3 months from Screening or 5 half-lives from Screening, whichever is longer
• Concomitant treatment with PPAR-alpha agonists (fibrates)
Drug: IVA337, Drug: Placebo
NASH - Nonalcoholic Steatohepatitis
Phase III, Nonalcoholic Steatohepatitis, NASH, Peroxisome proliferator-activated receptor (PPAR), Liver Diseases, Fibrosis
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 378 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| ARcare Center for Clinical Research Little Rock, Arkansas | Senthil Raghavan, Doctor |
| ARcare Center for Clinical Research - Conway Conway, Arkansas | Landon Humphrey, Doctor |
| ASHA Clinical Research - Munster Hammond, Indiana | Mohan Kesani, Doctor |
| Accel Research Sites Maitland, Florida | |
| Accelemed Research Institute Austin, Texas | Nomita Kim, Doctor |
| Acibadem City Clinic Tokuda Hospital Sofia, | Rozalina Balabanska, Doctor |
| Adobe Gastroenterology Tucson, Arizona | Sam Moussa, Doctor |
| Advanced Medical Trials Georgetown, Texas | Murray Snook, Doctor |
| Advanced Research Institute New Port Richey, Florida | Curtis Freedland, Doctor |
| AdventHealth Transplant Institute Orlando, Florida | Ayman Koteish, Doctor |
| Algemeen Ziekenhuis Delta - Campus Rumbeke Roeselare, West-Vlaanderen | Charlotte De Vloo, Doctor |
| Algemeen Ziekenhuis Maria Middelares Ghent, | Christophe Van Steenkiste, Doctor |
| Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan Bruges, | Christophe Schoonjans, Doctor |
| Allure Health, Llc Friendswood, Texas | Soto Efrain, Doctor |
| Alpha Research Institute, LLC Houston, Texas | Nicola Abate, Doctor |
| American Research Centers of Florida Pembroke Pines, Florida | Luis del Prado Rodriguez, Doctor |
| American Research Institute, Inc Cutler Bay, Florida | |
| Amsterdam Universitair Medische Centra - Vrije Universiteit Medisch Centrum Amsterdam, Noord-Holland | Adriaan Holleboom, Doctor |
| Arizona Digestive Health - Sun City Sun City, Arizona | Parag Chokshi, Droctor |
| Arizona Digestive Health - Sun City Sun City, Arizona | Parag Chokshi, Doctor |
| Arizona Liver Health Tucson, Arizona | Naim Alkhouri, Doctor |
| Arizona Liver Health - Peoria Peoria, Arizona | Ann Moore, Doctor |
| Arkansas Diagnostic Center Little Rock, Arkansas | Alonzo Williams, Doctor |
| Arkansas Gastroenterology North Little Rock, Arkansas | Scott Wofford, Doctor |
| Athens Gastroenterology Association Athens, Georgia | Jeffrey Williams, Doctor |
| Austin Health Heidelberg, Victoria | Marie Sinclair, Doctor |
| Aventiv Research - Columbus Columbus, Ohio | Samir Arora, Doctor |
| Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo, | Salvatore Petta, Doctor |
| Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara Novara, | Cristina Rigamonti, Doctor |
| Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi Bologna, | Francesco Axxaroli, Doctor |
| Barts Health NHS Trust London, Greater London | William Alazawi, Doctor |
| Beth Israel Deaconess Medical Center - Liver Center Boston, Massachusetts | Michelle Lai, Doctor |
| Bon Secours Liver Institute of Hampton Roads Newport News, Virginia | Mitchell Shiffman, Doctor |
| Boston Medical Center Boston, Massachusetts | Arpan Mohanty, Doctor |
| Bridgeport Hospital Bridgeport, Connecticut | Caroline Loeser, Doctor |
| Brooke Army Medical Center Fort Sam Houston, Texas | Johanna Marowske, Doctor |
| CHRU de Besançon - Hôpital Jean-Minjoz Besançon, Franche-Comté | Vincent Di Martino, Doctor |
| CHU Saint-Eloi Montpellier, Occitanie | Stéphanie Faure, Doctor |
| CHU de Lille - Hôpital Claude Huriez Lille, Hauts-de-France | Philippe Mathurin, Doctor |
| CHU de Limoges Limoges, | Véronique Loustaud Ratti, Doctor |
| Cadena Care Institute Poway, California | Kevin Merkes, Doctor |
| California Pacific Medical Center Research Institute San Francisco, California | Raphael Merriman, Doctor |
| Campbelltown Hospital Campbelltown, New South Wales | Vincent Ho, Doctor |
| Care United Medical Center - Forney Forney, Texas | Shilpi Mittal, Doctor |
| Carmel Medical Center Haifa, | Eli Zuckerman, Doctor |
| Carolina Digestive Diseases Greenville, North Carolina | |
| Centor for Advanced Gastroenterology - Main Office - Maitland Maitland, Florida | |
| Centre Hospitalier Universitaire De Nantes - Hôpital Nord Laennec Saint-Herblain, | Bertrand Cariou, Doctor |
| Centre Hospitalier Universitaire De Nantes - Hôpital Nord Laennec Saint-Herblain, | Bertand Cariou, Doctor |
| Centre Hospitalier Universitaire Estaing Clermont-Ferrand, Aubergne | Armando Abergel, Doctor |
| Centre Hospitalier Universitaire Grenoble Alpes Grenoble, Isère | Charlotte Costentin, Doctor |
| Centre Hospitalier Universitaire de Liège Site Sart Tilman Liège, | Jean Delwaide, Doctor |
| Centre Hospitalier Universitaire de Rennes Rennes, Ille-et-Vilaine | Edouard Bardou-Jacquet, Doctor |
| Centre Hosptitalier Universitaire d'Angers Angers, | Jerome Boursier, Doctor |
| Centre Hosptitalier Universitaire d'Angers Angers, | Jérôme Boursier, Doctor |
| Centre de Médecine Métabolique de Lanaudière Terrebonne, Quebec | Yves Robitaille, Doctor |
| Centro De Investigaciones Clínicas Viña Del Mar Viña del Mar, | Francisco Fuster Saldias, Doctor |
| Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria Lisboa, | Helena Cortez Pinto, Doctor |
| Centro Hospitalar Universitário de São João Porto, | Guilherme Macedo, Doctor |
| Centro Hospitalar de Trás-Os-Montes e Alto-Douro - Hospital de S. Pedro Vila Real, | Jose Presa Ramos, Doctor |
| Centro de Investigacion Medico Biologica y Terapia Avanzada Jalisco, | Efrain Montano, Doctor |
| Centro de Investigacion y Gastroenterologia Cuauhtémoc, | Alma Laura Ladron De Guevara Cetina, Doctor |
| Centrum Medyczne Pratia - Katowice Katowice, Slaskie | Elzbieta Blach, Doctor |
| Charité Universitätsmedizin Berlin Berlin, | Münevver Demir, Doctor |
| Charlotte Gastroenterology and Hepatology - Randolph Road Office Charlotte, North Carolina | Jason Wilson, Doctor |
| Chevy Chase Clinical Research Chevy Chase, Maryland | |
| Clinica Universidad de Navarra Pamplona, | Delia D'Avola, Doctor |
| Clinical Research Institute of Michigan Chesterfield, Michigan | Ronald Fogel, Doctor |
| Clinical Trial Management Services Thousand Oaks, California | Mahendra Patel, Doctor |
| Clinical Trials Services Corporation Miami, Florida | |
| Clinique Pasteur Toulouse, | Maeva Guillaume, Doctor |
| Cliniques Universitaires Saint-Luc Brussels, | Nicolas Lanthier, Doctor |
| Combined Gastro Research LLC Lafayette, Louisiana | Stephen Abshire, Doctor |
| Complejo Asistencial Universitario de Leon León, | Francisco Jorquera Plaza, Doctor |
| Complejo Hospitalario Torrecardenas Almería, | Marta Maria Casado Martín, Doctor |
| Complejo Hospitalario de Pontevedra Pontevedra, | Juan Turnes Vazquez, Doctor |
| Concord Repatriation General Hospital Concord, New South Wales | Alice Lee, Doctor |
| Consorci Corporació Sanitària Parc Taulí de Sabadell Sabadell, Barcelona | Meritxell Casas Rodrigo, Doctor |
| Consorci Hospital General Universitari de València Valencia, | Francisco Moises Diago Madrid, Doctor |
| Consultants for Clinical Research - Montgomery Office Cincinnati, Ohio | Ravi Ravinuthala, Doctor |
| Covenant Metabolic Specialists LLC - Sarasota Sarasota, Florida | Guy Neff, Doctor |
| Cumberland Research Associates Fayetteville, North Carolina | John Poulos, Doctor |
| Cure Clinical Research, LLC Fountain Valley, California | Ramprasad Dandillaya, Doctor |
| D&H National Research Centers Miami, Florida | Jorge Amaya, Doctor |
| Debreceni Egyetem Klinikai Központ Kenézy Gyula Campus Debrecen, Hajdú-Bihar | |
| Del Sol Research Management - Tucson East Tucson, Arizona | Fadi Deeb, Doctor |
| Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet Budapest, | Mihaly Makara, Doctor |
| Diagnostic Consultative Center Aleksandrovska Sofia, | Diana Stefanova-Petrova, Doctor |
| Diagnostic Consulting Center 20 - Sofia Еооd Sofia, | Dimitar Dimitrov, Doctor |
| Digestive & Liver Disease Specialists Norfolk, Virginia | Alan Tieu, Doctor |
| Digestive Disease Associates - Catonsville Catonsville, Maryland | |
| Digestive Health Associates of Texas - Rockwall Garland, Texas | Harry Sarles, Doctor |
| Digestive Health Research of Central Texas Waco, Texas | Hanumantha Ancha, Doctor |
| Digestive Health Research of North Texas Wichita Falls, Texas | Joshua Stagg, MD |
| Digestive Health Specialist of the Southeast Dothan, Alabama | Samuel Tarwater, Doctor |
| Digestive Healthcare of Georgia Atlanta, Georgia | Michael Galambos, Doctor |
| Digestive Specialists - Dayton Dayton, Ohio | Michael Sherman, Doctor |
| Doral Medical Research, LLC Hialeah, Florida | |
| Duke University Medical Center Durham, North Carolina | Anna Mae Diehl, Doctor |
| EPIMED Berlin, | Keikawus Arasteh, Doctor |
| EUGASTRO Leipzig, Sachsen | Ingolf Schiefke, Doctor |
| Eastern Health - Australia Box Hill, Victoria | Alexander Hodge, Doctor |
| Elisabeth-TweeSteden Ziekenhuis Tilburg, | Robert Laheij, Doctor |
| Emeritas Research Group Leesburg, Virginia | |
| Eminat, LLC Plantation, Florida | Yaneth Trujillo, Doctor |
| Erasmus Medisch Centrum Rotterdam, | William Brouwer, Doctor |
| Excel Medical Clinical Trials, LLC Boca Raton, Florida | Seth Baum, Doctor |
| Fiona Stanley Hospital Murdoch, Western Australia | Oyekoya Ayonrinde, Doctor |
| Florida Research Institute Tampa, Florida | Souvik Sarkar, Doctor |
| Florida Vascular Research Miami, Florida | Pablo Guala, Doctor |
| Fomatmedicalresearch Camarillo, California | Karen Simon, Doctor |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs Roma, | Luca Miele, Doctor |
| Franciscus Gasthuis & Vlietland Rotterdam, | Robert Roomer, Doctor |
| Froedtert and Medical College of Wisconsin Milwaukee, Wisconsin | Kia Saeian, MD |
| Fundación de Investigación de Diego Clinical Research San Juan, | Grisell Ortiz-Lasanta, Doctor |
| Fundação Faculdade Regional de Medicina de São José do Rio Preto São José do Rio Preto, São Paulo | Rita De Cassia Martins Alves Da Silva, Doctor |
| Future Care Solution Miami, Florida | Pilar Trueba, Doctor |
| GI Alliance - Texas Digestive Disease Consultants - Fort Worth - Downtown Dallas, Texas | Apurva Modi, Doctor |
| GI Select Health Research, LLC Richmond, Virginia | Omer Khalid, Doctor |
| GW Research Chula Vista, California | Gregory Wiener, Doctor |
| Gadolin Research Beaumont, Texas | |
| Galen Research Chesterfield, Missouri | Alexander Beyzer, Doctor |
| Galenus Group Lehigh Acres, Florida | Edgardo Castillo, Doctor |
| Gallipoli Medical Research Foundation Greenslopes, | Darrell Crawford, Doctor |
| Gastro Center of Maryland - Columbia Columbia, Maryland | Rudrajit Rai, Doctor |
| Gastro Clinic El Paso, Texas | |
| Gastro Florida Clearwater, Florida | Glamour Tejinder, Doctor |
| Gastro Health - Galloway Miami, Florida | Maria Hernandez, Doctor |
| Gastro One - Germantown Office - Wolf Park Drive Germantown, Tennessee | Ziad Younes, Doctor |
| Gastroenterologie am Bayerischen Platz Berlin, | Wolf Peter Hofmann, Doctor |
| Gastroenterologische Gemeinschaftspraxis Herne Herne, | Manfred Von Der Ohe, Doctor |
| Gastroenterology Associates - Baton Rouge Baton Rouge, Louisiana | John McDonald, Doctor |
| Gastroenterology Associates of Northern Virginia Fairfax, Virginia | Bezawit Tekola, Doctor |
| Gastroenterology Associates of Western Michigan Wyoming, Michigan | Allan Coates, Doctor |
| Gastroenterology Consultants - Ellington Houston, Texas | Natarajan Bala, Doctor |
| Gastrointestinal (GI) Associates L.L.P. Columbia, Missouri | Michael D. Williams, Doctor |
| Gastrointestinal Associates & Endoscopy Center - Flowood Flowood, Mississippi | Pierce Dotherow, Doctor |
| Genoma Research Group Miami, Florida | Angel Vento, Doctor |
| Grand Teton Research Group, PLLC Idaho Falls, Idaho | |
| Great Lakes Gastroenterology Research - Mentor Mentor, Ohio | Keith Friedenberg, Doctor |
| Hadassah University Hospital Ein Kerem Jerusalem, | Rifaat Safadi, Doctor |
| Headlands - Centex Studies - Westfield Houston, Texas | |
| Heartland Medical Research Clive, Iowa | Rajalakshmi Iyer, Doctor |
| Henry Ford Health System Detroit, Michigan | Humberto Gonzalez, Doctor |
| Heritage Medical Research Centre Calgary, Alberta | Laura Stinton, Doctor |
| Hi Tech and Global Research, LLC Coral Gables, Florida | Jorge Beato, Doctor |
| High Tech Medical Kft. Budapest, | Tamas NYeKY, Doctor |
| Hopital Cochin Paris, | Stanislas Pol, Doctor |
| Hopital Rangueil Toulouse, | Christophe Bureau, Doctor |
| Hopital Saint-Joseph Marseille, Bouches-du-Rhône | Marc Bourlière, Doctor |
| Hopital de la Croix Rousse Lyon, | Massimo Levrero, Doctor |
| Hopitaux De Brabois Nancy, | Jean-Pierre Bronowicki, Doctor |
| Hopitaux De Brabois Nancy, | Jean-Pierre Bronowicki, Doctor |
| Hospital Britanico de Buenos Aires Ciudad Autonoma Buenos Aires, | Luis Colombato, Doctor |
| Hospital Clinic de Barcelona Barcelona, | Pere Gines Gibert, Doctor |
| Hospital Clinico Universitario Lozano Blesa Zaragoza, | |
| Hospital Clinico Universitario de Santiago Santiago, | Esther Molina Perez, Doctor |
| Hospital Clinico Universitario de Valencia Valencia, | Maria Desamparados Escudero Garcia, Doctor |
| Hospital Da Senhora da Oliveira - Guimarães Guimarães, | Joana Magalhães, Doctor |
| Hospital De La Santa Creu I Sant Pau Barcelona, | German Soriano Pastor, Doctor |
| Hospital Ernesto Dornelles Porto Alegre, | Guilherme Sander, Doctor |
| Hospital General Universitario Gregorio Marañon Madrid, | Luis Ibanez Samaniego, Doctor |
| Hospital Germans Trias I Pujol Badalona, | Rosa Morillas Cunill, Doctor |
| Hospital Italiano La Plata La Plata, Buenos Aires | Raúl Eduardo Adrover, Doctor |
| Hospital Pedro Hispano Senhora Da Hora, | Filipe Andrade, Doctor |
| Hospital Provincial del Centenario Rosario, Santa Fe Province | Fernando Bessone, MD |
| Hospital San Juan de Dios de La Serena La Serena, Coquimbo | Jose Miguel Valera Millas, Doctor |
| Hospital Universitari Vall d'Hebron Barcelona, | Victor Vargas, Doctor |
| Hospital Universitario Austral Pilar, | Marcelo Silva, Doctor |
| Hospital Universitario Doctor José Eleuterio Gonzalez Monterrey, Nuevo León | Linda Elsa Munoz Espinoza, Doctor |
| Hospital Universitario Fundacion Alcorcon Alcorcón, | |
| Hospital Universitario Marqués de Valdecilla Santander, | Javier Crespo Garcia, Doctor |
| Hospital Universitario Miguel Servet Zaragoza, | Vanesa Bernal, Doctor |
| Hospital Universitario Puerta De Hierro - Majadahonda Madrid, | Jose Luis Calleja Panero, Doctor |
| Hospital Universitario Rio Hortega Valladolid, | Irene Penas, Doctor |
| Hospital Universitario Son Espases Palma de Mallorca, | Maria Lucia Bonet Vidal, Doctor |
| Hospital Universitario Virgen de Valme Seville, | Mercedes Serrano Romero, Doctor |
| Hospital Universitario Virgen de la Victoria Málaga, | Francisco Tinahones, Doctor |
| Hospital Universitario Virgen del Rocio Seville, | Manuel Romero Gomez, Doctor |
| Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo São Paulo, | Claudia De Oliveira, Doctor |
| Hospital das Clinicas da Universidade Federal de Minas Gerais Belo Horizonte, Minas Gerais | Claudia Couto, Doctor |
| Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Monte Alegre, | Roberta Araujo, Doctor |
| Hospital de Braga Braga, | Carla Rolanda, Doctor |
| Hospital de Clínicas de Porto Alegre Porto AlegreRS, | Mário Da Silva, Doctor |
| Houston Methodist Hospital Houston, Texas | David Victor, Doctor |
| Hôpital Erasme Brussels, | Christophe Moreno, Doctor |
| Hôpital Haut-Lévêque Pessac, | Victor De Ledinghen, Doctor |
| Hôpital Haut-Lévêque Pessac, | Victor De Leginghen, Doctor |
| Hôpital Hautepierre Strasbourg, Bas-Rhin | Laurence Serfaty, Doctor |
| Hôpital Saint-Antoine Paris, | Marie Lequoy, Doctor |
| Hôpital Universitaire Pitié Salpêtrière Paris, | Vlad Ratziu, Doctor |
| Hôpital l'Archet Nice, Provence-Alpes-Côte d'Azur | Albert Tran, Doctor |
| Hôpitaux Universitaires Henri Mondor Créteil, | Vincent Leroy, Doctor |
| Hôpitaux Universitaires Paris Nord Val-de-Seine - Hôpital Beaujon Clichy, Ile-de-France | Laurent Castera, Doctor |
| Hôpitaux Universitaires Paris-Sud - Hôpital Paul Brousse Villejuif, Ile-de-France | Didier Samuel, Doctor |
| IACT Health Columbus, Georgia | Michael Steinbook, Doctor |
| ID Clinic Myslowice, | Ewa Janczewska, Doctor |
| IMIC Research - International Medical Investigations Centers Palmetto Bay, Florida | Miguel Rodriguez, Doctor |
| Icahn School of Medicine at Mount Sinai New York, New York | Augusto Villanueva, Doctor |
| Impact Research Institute Waco, Texas | Nadege Gunn, Doctor |
| Inova Medical Group - Fairfax Hospital Falls Church, Virginia | Stephen Clement, Doctor |
| Integris Baptist Medical Center Oklahoma City, Oklahoma | Joykumar Patel, Doctor |
| Investigaciones Medicas Cisneros Monterrey, Nuevo León | |
| Investigative Clinical Research - Annapolis Annapolis, Maryland | Epstein Michael, Doctor |
| JY Research Institute Inc. Cutler Bay, Florida | |
| John Hunter Hospital New Lambton Heights, New South Wales | Lay Theng Gan, Doctor |
| Kansas Medical Clinic - Gastroenterology Topeka, Kansas | Shekhar Challa, Doctor |
| King's College Hospital NHS Foundation Trust London, | Kaushik Agarwal, Doctor |
| Klinikum Chemnitz Chemnitz, | Th. Till Wissniowski, Doctor |
| Klinische Forschung Karlsruhe GmbH Karlsruhe, Baden-Württemberg | Julia Chevts, Doctor |
| Life Medical Research Group Miami, Florida | Sander Fernandez, Doctor |
| Liver Associates of Texas Houston, Texas | Victor Ankoma-Sey, Doctor |
| Liver Specialists of Texas Houston, Texas | Joseph Galati, Doctor |
| Liver Specialists of Texas Houston, Texas | Joseph Galati, MD |
| Liverpool Hospital Liverpool, New South Wales | Scott Davison, Doctor |
| Lone Peak Family Health Draper, Utah | David Jack, Doctor |
| Louisiana Research Center LLC Shreveport, Louisiana | Humberto Aguilar, Doctor |
| Lucas Research, Inc Morehead City, North Carolina | Kathryn Lucas, Doctor |
| MIND Klinika Budapest, | Tibor Gyokeres, Doctor |
| MNGI Digestive Health - Northeast Minneapolis Clinic Minneapolis, Minnesota | Ibrahim Hanouneh, Doctor |
| Massachusetts General Hospital Boston, Massachusetts | Kathleen Corey, Doctor |
| Mayo Clinic - Rochester Rochester, Minnesota | Harmeet Malhi, Doctor |
| MedBio Trials Miami, Florida | |
| Medical Center Center of Family Medicine Plus, LLC Kyiv, | |
| Medical Center Edelweiss Medics, LLC Kyiv, | |
| Medical Center Medbud-Clinic, LLC Kyiv, | |
| Medical Center Medica Plus Veliko Tarnovo, | Ilko Kosturkov, Doctor |
| Medical University of South Carolina Charleston, South Carolina | Don Rockey, Doctor |
| Medizinische Universitat Innsbruck Innsbruck, | Heinz Zoller, Doctor |
| Mercy Medical Center - McAuley Plaza Baltimore, Maryland | Paul Thuluvath, Doctor |
| Meritus Center for Clinical Research Hagerstown, Maryland | |
| Metropolitan Gastroenterology Associates - Metairie Metairie, Louisiana | George Catinis, Doctor |
| Miami Dade Medical Research Institute Miami, Florida | Orlando Puente, Doctor |
| Mid-Atlantic GI Research Greenbelt, Maryland | Raja Mohi-ud-din, Doctor |
| Monash Medical Centre Clayton, Victoria | Stephen Pianko, Doctor |
| NAPA Research Pompano Beach, Florida | Naval Parikh, Doctor |
| NECCR Prima Care Research, LLC Fall River, Massachusetts | |
| National Research Institute - Panorama City Panorama City, California | Robert Jenders, Doctor |
| National Research Institute - Santa Ana Huntington Park, California | Julie Vu, Doctor |
| National Research Institute - Westlake Los Angeles, California | Leibowitz Mark, Doctor |
| Nepean Hospital Kingswood, New South Wales | Martin Weltman, Doctor |
| Niepubliczny Zaklad Opieki Zdrowotnej Centrum Badan Klinicznych Wrocław, Dolnoslaskie | Napora Piotr, Doctor |
| North Alabama GI Research Center llc Madison, Alabama | Jason Lockette, Doctor |
| North Shore Gastroenterology Westlake, Ohio | Mousab Tabbaa, Doctor |
| NorthShore University Healthsystem Evanston, Illinois | Liana Billings, Doctor |
| Nov Rehabilitatsionen Tsentar EOOD Stara Zagora, | |
| Objective Health - Birmingham Gastroenterology Associates Birmingham, Alabama | Charles Dasher, Doctor |
| ObjectiveGI - Northeast GI Research Concord, North Carolina | Matthew Myers, Doctor |
| Office of Franco Felizarta, MD Bakersfield, California | Franco Felizarta, Doctor |
| Optimus U Corporation Miami, Florida | Yaneicy Gonzalez Rojas, Doctor |
| Options Health Research Tulsa, Oklahoma | Harvey Tatum, Doctor |
| Oracle Clinical Research College Park, Georgia | Linda Martinez, Doctor |
| Ospedale casa sollievo della sofferenza San Giovanni Rotondo, | Alessandra Mangia, Doctor |
| Palmetto Clinical Research Greenville, South Carolina | Colby Grossman, Doctor |
| Palmetto Research Hialeah, Florida | |
| PanAmerican Clinical Research - US Headquarters Brownsville, Texas | |
| PanAmerican Clinical Research Mexico - Cuernavaca Cuernavaca, Morelos | Guillermo Cabera Alvarez, Doctor |
| PanAmerican Clinical Research S.A. de C.V. Querétaro, | Jonathan Aguirre Valadez, Doctor |
| Panthera Biopartners - Glasgow Glasgow, North Lanarkshire | Mathis Heydtmann, Doctor |
| Panthera Biopartners - Manchester Manchester, England | Ramjee Mahadev, Doctor |
| Panthera Biopartners - Manchester Manchester, England | Mahadev Ramjee, Doctor |
| Panthera Biopartners - North London London, England | |
| Panthera Biopartners - Preston Preston, England | |
| Pensacola GI Research Center Pensacola, Florida | Elizabeth Maley, Doctor |
| Pinnacle Clinical Research - Austin Austin, Texas | Jacques Benun, Doctor |
| Pinnacle Clinical Research - San Antonio San Antonio, Texas | Madhavi Rudraraju, Doctor |
| Pinnacle Research Group Anniston, Alabama | Pankaj Kashyap, Doctor |
| Pioneer Research Solutions Houston, Texas | Francisco Velazquez, Doctor |
| Pontificia Universidad Católica de Chile - Escuela de Medicina Santiago, | Marco Arrese Jiménez, Doctor |
| Precision Research Institute San Diego, California | |
| Pro Live Medical Research Miami, Florida | Rosa Suarez, Doctor |
| Prospective Research Innovations Inc. Rancho Cucamonga, California | David Scarpino, Doctor |
| Quality Research - San Antonio San Antonio, Texas | Robert Morin, Doctor |
| Quest Clinical Research San Francisco, California | Maurizio Bonacini, Doctor |
| Radboud Universitair Medisch Centrum Nijmegen, | Joost Drenth, Doctor |
| Rambam Health Care Campus Haifa, | Ella Veitsman, Doctor |
| Rapid City Medical Center Rapid City, South Dakota | Blake Jones, Doctor |
| Regional Infectious Diseases and Infusion Center LaGrange, Georgia | Ravi Kamepalli, Doctor |
| Research Site S.R.O. Pilsen, | Vaclav Hejda, Doctor |
| Research and Education Foundation of Atlanta Medical Center Atlanta, Georgia | |
| Research and Education, Inc. San Diego, California | Tuan Nguyen, Doctor |
| Richmond University Medical Center Staten Island, New York | Kavan Patel, Doctor |
| Royal Brisbane and Women's Hospital Herston, Queensland | Richard Skoien, Doctor |
| Royal Perth Hospital Perth, | Nicholas Kontorinis, Doctor |
| Royal Surrey County Hospital NHS Foundation Trust Surrey Quays, England | Marinos Pericleous, Doctor |
| SC Clinical Research Garden Grove, California | |
| SKYCRNG - Quinn Healthcare Ridgeland, Mississippi | |
| SSM Health Saint Louis University Hospital St Louis, Missouri | Brent Neuschwander-Tetri, Doctor |
| Saint Joseph's Hospital and Medical Center Phoenix, Arizona | Justin Reynolds, Doctor |
| Saint Luke's Hospital of Kansas City Kansas City, Missouri | |
| San Fernando Valley Health Institute West Hills, California | Dan Streja, Doctor |
| Schiff Center for Liver Diseases Miami, Florida | Eugene Schiff, Doctor |
| Sefako Makgatho Health Sciences University Pretoria, Gauteng | |
| Sensible Healthcare Clinical Research Ocoee, Florida | William Kelly Bowman, Doctor |
| Shaare Zedek Medical Center Jerusalem, | Gadi Lalazar, Doctor |
| Sherman Clinical Research Sherman, Texas | Irfanullah Yusufzai, Doctor |
| Silicon Valley Research Institute San Jose, California | Huy Trinh, Doctor |
| Soma Clinical Trials Denison, Texas | Hesham Elgouhari, Doctor |
| Soroka Medical Center Beersheba, | Ohad Etzion, Doctor |
| South Texas Research Institute - Brownsville Brownsville, Texas | Rashmee Patil, Doctor |
| South Texas Research Institute - Edinburg Edinburg, Texas | Rashmee Patil, Doctor |
| Southeast Clinical Research Center Dalton, Georgia | Pablo E. Perez, Doctor |
| Southwest Gastroenterology Associates Albuquerque, New Mexico | Antoine Jakiche, Doctor |
| St. Josefs-Hospital Wiesbaden Wiesbaden, Hessen | Christoph Sarrazin, Doctor |
| St. Joseph's Healthcare Hamilton - Charlton Campus Hamilton, Ontario | Keith Tsoi, Doctor |
| Stanford University Medical Center Palo Alto, California | Natalie Torok, Doctor |
| State University of New York - University at Buffalo Buffalo, New York | Ajay Chaudhuri, Doctor |
| Summitt - Pinnacle Clinical Research - Georgetown Georgetown, Texas | Jacques Benun, Doctor |
| Sun Research Institute San Antonio, Texas | Leonel Reyes, Doctor |
| Synergy Healthcare Bradenton, Florida | Patrick Weston, Doctor |
| Synexus - Częstochowa Czestochowa, Śląskie | Jamrozik-Kruk Zofia, Doctor |
| Synexus - Gdynia Gdynia, Pomorskie | Orkwiszewska-Nalewajko Anna, Doctor |
| Synexus - Helderberg Clinical Research Centre - Somerset West Somerset West, Western Cape | Soritha Coetzer, Doctor |
| Synexus - Katowice Katowice, Slaskie | Magdalena Olszanecka-Glinianowicz, Doctor |
| Synexus - Mediclinic Southern Africa - Constantiaberg Cape Town, Western Cape | |
| Synexus - Poznań Poznań, Wielkopolskie | Elżbieta Kołodziejska, Doctor |
| Synexus - Warszawa Warszawa, Mazowieckie | |
| Synexus - Wrocław Wrocław, Dolnoslaskie | Marek Dwojak, Doctor |
| Synexus - Łódź Łódź, Łódzkie | Marcin Ojrzanowski, Doctor |
| Synexus Clinical Research SA- Watermeyer Pretoria, | Nontokozo Mkhize, Doctor |
| Synexus Czech - DRS Prague Praha, | Smid Vaclav, Doctor |
| Synexus Magyarorszag Egeszsegugyi Szolgaltato Kft Budapest, Central Hungary | Alajos Takats, Doctor |
| Synexus Magyarország Egészségügyi Szolgáltató Kft. - Debrecen Debrecen, Hajdu-Bihar County | |
| Synexus Polska Sp. z o.o. Oddzial w Gdansku Gdańsk, | |
| Tampa Bay Medical Research Clearwater, Florida | Sureka Bollepalli, Doctor |
| Tampa General Hospital Tampa, Florida | Nyingi Kemmer, Doctor |
| Tandem Clinical Research Marrero, Louisiana | |
| Tandem Clinical Research GI Marrero, Louisiana | Conar Fitton, Doctor |
| Tandem Clinical Research GI, LLC Marrero, Louisiana | Adil Fatakia, Doctor |
| Tel Aviv Sourasky Medical Center Tel Aviv, | Helena Katchman, Doctor |
| Texas Clinical Research Institute Arlington, Texas | Reem Ghalib, Doctor |
| Texas Liver Institute/American Research Corporation San Antonio, Texas | Eric Lawitz, Doctor |
| The Chaim Sheba Medical Center Ramat Gan, | Ziv Ben-Ari, Doctor |
| The Clinical Trials Network - Gastro Care Institute Lancaster, California | Kumaravel Perumalsamy, Doctor |
| The Institute for Liver Health - Chandler Chandler, Arizona | Anita Kohli, Doctor |
| The Liver Institute At Methodist Dallas Dallas, Texas | Parvez Mantry, Doctor |
| The Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne, | Quentin Anstee, Doctor |
| Top Medical Research Cutler Bay, Florida | Jose Ruiz, Doctor |
| Topography Health, Inc. Manassas, Virginia | Myung Choi, Doctor |
| Toronto Digestive Disease Associates Vaughan, Ontario | Susan Greenbloom, Doctor |
| Tranquil Clinical Research Webster, Texas | Jignesh Shah, Doctor |
| TriWest Research Associates El Cajon, California | Donald Lipkis, Doctor |
| USPA Advance Concept Medical Research Group Miami, Florida | Francisco Macias, Doctor |
| Unidade Local Saúde Alto Minho - Hospital de Santa Luzia Viana Do Castelo, | Tarcisio Araujo, Doctor |
| Universita degli Studi di Napoli Federico II Napoli, | Filomena Morisco, Doctor |
| Universitair Medisch Centrum Utrecht Utrecht, | Karel Van Erpecum, Doctor |
| Universitair Ziekenhuis Antwerpen Edegem, | Sven Francque, Doctor |
| Universitair Ziekenhuis Gent Ghent, | Anja Geerts, Doctor |
| Universitair Ziekenhuis Leuven - Campus Gasthuisberg Leuven, Flemish Brabant | Jef Verbeek, Doctor |
| University Health Network Toronto, Ontario | Florence Wong, Doctor |
| University Hospitals Case Medical Center Cleveland, Ohio | Pierre Gholam, Doctor |
| University Multiprofile Hospital for Active Treatment St. Ivan Rilski Sofia, | Deian Jelev, Doctor |
| University Multiprofile Hospital for Active Treatment and Emergency Medicine N.I. Pirogov Sofia, Sofia City | Kamen Danov, Doctor |
| University of Iowa Hospitals and Clinics Iowa City, Iowa | Antonio Sanchez, Doctor |
| University of Kansas Medical Center Research Institute Kansas City, Kansas | Winston Dunn, Doctor |
| University of Kentucky Lexington, Kentucky | Alla Grigorian, Doctor |
| University of Michigan Health-West Hospital Wyoming, Michigan | Ammar Hassan, Doctor |
| University of Pittsburgh Medical Center Pittsburgh, Pennsylvania | Jaideep Behari, Doctor |
| University of Utah School of Medicine Salt Lake City, Utah | Juan Gallegos-Orozco, Doctor |
| University of Virginia Health System Charlottesville, Virginia | Stephen Caldwell, Doctor |
| Universitätsklinikum Carl Gustav Carus Dresden Dresden, | Marco Berning, Doctor |
| Universitätsklinikum Schleswig-Holstein - Campus Lübeck Lübeck, Schleswig-Holstein | Jens Marquardt, Doctor |
| Universitätsklinikum des Saarlandes Homburg, | Marcin Krawczyk, Doctor |
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz, | Jörn Schattenberg, Doctor |
| VITAZ Sint-Niklaas, | Jeoffrey Schouten, Doctor |
| Vanderbilt University Medical Center Nashville, Tennessee | Andrew Scanga, Doctor |
| Velocity Clinical Research - Austin Cedar Park, Texas | Gregg Lucksinger, Doctor |
| Velocity Clinical Research, Chula Vista Chula Vista, California | Michael Waters, Doctor |
| Veterans Affairs Pittsburgh Healthcare System - University Drive Campus Pittsburgh, Pennsylvania | Obaid Shaikh, Doctor |
| Virginia Commonwealth University Richmond, Virginia | Velimir Luketic, Doctor |
| Washington University School of Medicine in St. Louis St Louis, Missouri | Kevin Korenblat, Doctor |
| Weill Cornell Medical College New York, New York | Sonal Kumar, Doctor |
| Western Galilee Hospital-Nahariya Nahariya, Northern District | Assy Nimer, Doctor |
| William Osler Health System - Brampton Civic Hospital Brampton, Ontario | Natasha Chandok, Doctor |
| Yale School of Medicine New Haven, Connecticut | Joseph Lim, Doctor |
| Ziekenhuis Bernhoven Uden, North Brabent | Ingrid Gisbertz, Doctor |
| Ziekenhuis Oost-Limburg - Campus Sint-Jan Limbourg, | Mathieu Struyve, Doctor |
| hospital Italiano de Buenos Aires Ciudad Autónoma de Buenos Aires (caba), Buenos Altes | Paola Casciato, Doctor |
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer Clinical Trials Contact - clinical-trials-contact@bayer.com
Paul, Asit, K.
NCT04464226
HM20024689
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
* Participants enrolled in any Bayer-sponsored darolutamide feeder study at the time of study closure or primary completion, who are currently receiving darolutamide and are experiencing clinical benefit from treatment.
* Participants who have not met any treatment discontinuation criteria in the feeder study protocol.
* Willingness to continue practicing acceptable methods of birth control during the study.
Exclusion Criteria:
* Participant is unable to comply with the requirements of the study.
* Negative benefit/ risk ratio as determined by the investigator.
* Meet any criteria for treatment discontinuation of the feeder study the participant is coming from. DRUG: Darolutamide (Nubeqa, BAY1841788)
Cancer
Roll-Over Study
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 383 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| 2nd Affiliated Hosp. of Shantou University Medical College Shantou, Guangdong | |
| ANDROGEOS, spol. s r.o. Prague, | |
| AS "Association of Health Centers" polyclinic "Elite" Riga, | |
| AZ Groeninge Campus Kennedylaan Kortrijk, | |
| Academisch Medisch Centrum (AMC) Amsterdam, | |
| Adelaide Cancer Centre Research Pty Ltd Kurralta Park, South Australia | |
| Advent Health Medical Group Urology Orlando, Florida | |
| Akademiska Sjukhuset Uppsala, | |
| Albert Schweitzer Ziekenhuis | Dordwijk - Cardiology Department Dordrecht, | |
| Andrews & Patel Associates Camp Hill, Pennsylvania | |
| Anhui Provincial Hospital Hefei, Anhui | |
| Anne Arundel Health System Annapolis, Maryland | |
| Asahi General Hospital Asahi, Chiba | |
| Asan Medical Center - Oncology Department Seoul, Seoul Teugbyeolsi | |
| Associated Medical Professionals of NY, PLLC Syracuse, New York | |
| Associação Hospitalar Beneficente São Vicente de Paulo Passo Fundo, Rio Grande do Sul | |
| Azienda Ospedaliero Universitaria Parma Parma, Emilia-Romagna | |
| Azienda Ospedaliero-Universitaria San Luigi Gonzaga - Oncologia Medica Orbassano, Piedmont | |
| Beijing Cancer Hospital - Oncology Department Beijing, Beijing Municipality | |
| Beijing Cancer Hospital - Oncology Department Beijing, Beijing Municipality | |
| Beijing Hospital Beijing, Beijing Municipality | |
| Boca Raton Regional Hospital - Oncology Boca Raton, Florida | |
| Bon Secours St. Francis Hospital Greenville, South Carolina | |
| CHLC - Hospital Sao Jose Lisbon, | |
| CHU Tours - Hôpital Bretonneau Tours, | |
| CHU UCL Namur Namur, | |
| CIUSSS de l'Estrie- Centre Haute-Yamaska Granby, Quebec | |
| CNE "Clinical Center of Oncology, Hematology, Transplantology and Palliative Care of the Cherkasy Regional Council" Cherkasy, | |
| COT Centro Oncologico do Triangulo Ltda Uberlândia, Minas Gerais | |
| CU Saint-Luc/UZ St-Luc Bruxelles - Brussel, | |
| CUIMED s.r.o Bratislava, | |
| Calderdale and Huddersfield NHS Foundation Trust¦Huddersfield Royal Infirmary - Oncology Huddersfield, West Yorkshire | |
| Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center Shenzhen, | |
| Cancer Hospital, Chinese Academy of Medical Sciences Beijing, | |
| Cancercare Outeniqua George, Eastern Cape | |
| Cancercare Rondebosch Oncology Cape Town, | |
| Cape Gate Oncology Centre Cape Town, Western Cape | |
| Cardiff and Vale University Health Board | University Hospital of Wales - Nephrology and Transplant Cardiff, | |
| Carolina Urological Research Center Myrtle Beach, South Carolina | |
| Centre Hospitalier Universitaire - Angers Angers, | |
| Centre Hospitalier de L'Universite de Montreal (CHUM) Montreal, Quebec | |
| Centre Jean Perrin Clermont-Ferrand, | |
| Centre Medico-Chirurgical Foch Suresnes, | |
| Centre d'Oncologie de Gentilly Nancy, | |
| Centre d'Oncologie et de Radiologie du Parc Dijon, | |
| Centro Hospitalar Universitario de Sao Joao | Polo Porto - Centro de Investigacao e Ensaios Clinicos Porto, | |
| Centro Médico Monte Carmelo - Oncology Department La Victoria, Arequipa | |
| Centro de Urología Buenos Aires, Ciudad Auton. de Buenos Aires | |
| Centrum Onkologii - Instytut im. M.Sklodowskiej-Curie Warsaw, | |
| Chang Gung Memorial Hospital at Linkou Taoyuan District, | |
| Charing Cross Hospital London, | |
| Charleston Oncology - Downtown Charleston, South Carolina | |
| Chelyabinsk Regional Oncology Dispensary Chelyabinsk, | |
| Chesapeake Urology Associates - Towson Baltimore, Maryland | |
| Chiba Cancer Center Chiba, Chiba | |
| China Medical University Hospital Taichung, | |
| Chongqing Cancer Hospital Chongqing, Chongqing Municipality | |
| Chonnam National University Hospital Gwangju, | |
| Chu De Liege Liège, | |
| Chu Rennes - Hopital Pontchaillou Rennes, | |
| Chungbuk National University Hospital Cheongju-si, | |
| City Outpatient Clinic #1 of Privolzhsky Regional Med. Cent. Nizhny Novgorod, | |
| City clinical hospital #40 Moscow Moscow, | |
| City of Hope National Medical Center Duarte, California | |
| Ciutat Sanitària i Universitaria de la Vall d'Hebron Barcelona, | |
| Clalit Health | Soroka Medical Center - Internal Medicine Department Beersheba, | |
| Clatterbridge Centre for Oncology Bebington, Merseyside | |
| Clinical Center Nis Niš, | |
| Clinical Hospital Center Bezanijska Kosa Belgrade, | |
| Clinical Oncological Dispensary of Omsk Region Omsk, | |
| Clinique Lanroze Brest, | |
| Clínica de Neoplasias Litoral Ltda Itajaí, Santa Catarina | |
| Complex Oncology Center - Vratsa Vratsa, | |
| Cross Cancer Institute Edmonton, Alberta | |
| Daugavpils Regional Hospital Daugavpils, | |
| Debreceni Egyetem Klinikai Kozpont Debrecen, | |
| Dept Radiation and Oncology Tygerberg Academic Hospital Cape Town, Western Cape | |
| Dudley Group NHS Foundation Trust ¦Russells Hall Hopsital - Oncology Dudley, West Midlands | |
| EMC Instytut Medyczny SA Wroclaw, | |
| ETG Network Spolka z o.o. Lodz, | |
| ETZ TweeSteden Ziekenhuis (vh Maria Ziekenhuis) Tilburg, | |
| East Suffolk and North Essex NHS Foundation Trust¦Colchester General Hospital - Oncology Trials Unit Colchester, Essex | |
| Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina Otwock, | |
| Fakultni nemocnice Kralovske Vinohrady Prague, | |
| First Urology PSC Jeffersonville, Indiana | |
| Friedrich-Schiller-Uni. Jena Jena, Thuringia | |
| Fudan University Shanghai Cancer Center - Oncology Department Shanghai, | |
| Fundación Oftalmológica de Santander Carlos Ardila Lule Floridablanca, Santander Department | |
| Fundação Pio XII - Hospital de Câncer de Barretos Barretos, | |
| G. Kenneth Jansz Medicine Professional Corporation Burlington, Ontario | |
| GZA Ziekenhuizen Wilrijk, | |
| Gabrail Cancer Center Canton, Ohio | |
| Gachon University Gil Medical Center Incheon, | |
| Gangnam Severance Hospital, Yonsei University Health System Seoul, | |
| Gazi Universitesi Tip Fakultesi Ankara, | |
| Gesundheitszentrum Holzminden Holzminden, Lower Saxony | |
| Gifu Prefectural General Medical Center Gifu, | |
| Gunma University Hospital Gunma, Maebashi | |
| Gustave Roussy - Departement Oncologie-Radiotherapie Villejuif, | |
| HCL - Centre Hospitalier Lyon Sud Pierre-Bénite, | |
| HUS, Meilahden sairaala Helsinki, Uusimaa | |
| HagaZiekenhuis Sgravenhage, | |
| Hamamatsu University Hospital Shizuoka, Hamamatsu, | |
| Health Corporation of the Ziv Medical Center (R.A.) Safed, | |
| Heinrich-Heine-Universität Düsseldorf Düsseldorf, North Rhine-Westphalia | |
| Henry Ford Hospital - OB/GYN Detroit, Michigan | |
| Hiroshima City Hiroshima Citizens Hospital Hiroshima, | |
| Hopital Charles Nicolle Rouen, | |
| Hopital Hotel Dieu - Nantes Nantes, | |
| Hopital Saint Louis Paris, Île-de-France Region | |
| Hosp Clínicas Facult. Med. de Ribeirão Preto / USP Ribeirão Preto, São Paulo | |
| Hosp. Araujo Jorge da Associação de Combate ao Câncer Goiânia, Goiás | |
| Hospital Amaral Carvalho Jaú, São Paulo | |
| Hospital Arnau De Vilanova De Valencia - Oncologia Valencia, | |
| Hospital Central de la Fuerza Aerea del Perú Lima, | |
| Hospital Clinic i Provincial de Barcelona Barcelona, | |
| Hospital Clinico Universitario San Carlos | Oncologia Madrid, | |
| Hospital Clinico de Salamanca Salamanca, | |
| Hospital Del Mar Barcelona, | |
| Hospital Evangélico de Cachoeiro de Itapemirim Cachoeiro de Itapemirim, Espírito Santo | |
| Hospital General Universitario Gregorio Marañón | Oncología Madrid, | |
| Hospital General de Elche - Urologia Elche, Alicante | |
| Hospital Pablo Tobon Uribe Medellín, Antioquia | |
| Hospital SAS de Jerez de la Frontera Jerez de la Frontera, Cádiz | |
| Hospital San Pedro de Alcántara - Oncologia Cáceres, | |
| Hospital Sao Rafael Salvador, | |
| Hospital Universitari Son Espases - Oncologia Palma de Mallorca, Illes Baleares | |
| Hospital Universitari de Bellvitge (HUB) Barcelona, | |
| Hospital Universitario "José Eleuterio González" Monterrey, Nuevo León | |
| Hospital Universitario 12 de Octubre Madrid, | |
| Hospital Universitario Fundacion Alcorcon - Urologia Alcorcón, Madrid | |
| Hospital Universitario Fundacion Jimenez Diaz Madrid, | |
| Hospital Universitario Lucus Augusti - Urologia Lugo, | |
| Hospital Universitario Ramon Y Cajal - Oncologia Madrid, | |
| Hospital Universitario Reina Sofia - Oncologia Córdoba, | |
| Hospital Universitario Virgen De La Victoria - Oncology Málaga, | |
| Hospital Universitario Virgen Del Rocio S.L. - Oncologia Seville, | |
| Hospital de Manacor - Urologia Manacor, Illes Baleares | |
| Hospital de la Santa Creu i de Sant Pau | Oncología Barcelona, | |
| Hospital of LT University of Health Sciences Kaunas Clinics Kaunas, | |
| Huadong Hospital, Affiliated to Fudan University Shanghai, | |
| Hubei Cancer Hospital Wuhan, Hubei | |
| Hunan Cancer Hospital - Oncology Department Changsha, Hunan | |
| Huntsman Cancer Institute Salt Lake City, Utah | |
| Hôpital d'Instruction des Armées Begin Saint-Mandé, | |
| Hôpital de la Milétrie Poitiers, | |
| IBCC - Instituto Brasileiro de Controle do Cancer São Paulo, São Paulo | |
| ICM - Institut du Cancer de Montpellier - Val d'Aurelle Montpellier, | |
| IEP São Lucas São Paulo, São Paulo | |
| INBIOMEDyC Querétaro Querétaro City, Querétaro | |
| IPO Lisboa Lisbon, | |
| IPO Porto Porto, | |
| IRCCS Istituto Nazionale Tumori Fondazione Pascale Napoli, Campania | |
| Illinois CancerCare - Peoria Peoria, Illinois | |
| Inje University Busan Paik Hospital BusanjinGu, Busan Gwang'yeogsi | |
| Inova Schar Cancer Insitute - Inova Fairfax Hospital Fairfax, Virginia | |
| Inst. de Assistência Médica ao Sérvidor Público Estadual São Paulo, São Paulo | |
| Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale Bordeaux, | |
| Institut Paoli-Calmettes - Marseille Marseille, | |
| Institut de Cancerologie Jean Godinot - Departement oncologie medicale Reims, | |
| Institut de Cancerologie Ouest - Saint-Herblain Saint-Herblain, | |
| Instituto Peruano de Oncología & Radioterapia - Oncologia SA - Oncology Department Lima, | |
| Instituto Valenciano de Oncologia Valencia, | |
| Instituto do Cancer do Ceara Fortaleza, | |
| Instituto do Câncer do Estado de São Paulo São Paulo, São Paulo | |
| Institutul Clinic Fundeni Bucharest, | |
| Irmandade Santa Casa de Misericordia de Porto Alegre | Oncology Porto Alegre, Rio Grande do Sul | |
| Ironwood Cancer and Research Centers - Chandler I Chandler, Arizona | |
| Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS Turin, Piedmont | |
| Istituto Oncologico Veneto_Padova - UOC Oncologia 1 Padua, Veneto | |
| Ivanovo Regional Oncology Dispensary Ivanovo, | |
| J. BREZA MEDICAL s. r. o. Bratislava, | |
| Jesse Brown VA Medical Center - Cardiology Chicago, Illinois | |
| Jiangsu Cancer Hospital Nanjing, Jiangsu | |
| Johns Hopkins Hospital - Pulmonology Baltimore, Maryland | |
| Juntendo University Hospital Bunkyō City, | |
| KO-MED Centra Kliniczne Lublin II Lublin, | |
| Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, | |
| Karolinska Universitetssjukhuset Stockholm, | |
| Keimyung University Dongsan Medical Center Daegu, | |
| Keio University Hospital Shinjuku-ku, Tokyo | |
| Keski-Suomen sairaala Nova Jyväskylä, | |
| Kindai University Hospital Sakai, Osaka | |
| Kingston Health Sciences Centre Kingston, Ontario | |
| Kitasato University Hospital Sagamihara, | |
| Kobe University Hospital Kobe, Hyōgo | |
| Krasnoyarsk Regional Clinical Oncology Dispensary Krasnoyarsk, | |
| Kyiv City Hospital #3 - Department of Urology Kyiv, | |
| Kyorin University Hospital Mitaka-shi, Tokyo | |
| Kyungpook National University Chilgok Hospital Deagu, | |
| LLC Reafan Novosibirsk, | |
| Langehoven Drive Oncology Centre Port Elizabeth, Eastern Cape | |
| Leningrad Regional Oncology Dispensary Saint Petersburg, | |
| Liaoning Cancer Hospital and Institute Shenyang, Liaoning | |
| Liga Norte Riograndense Contra o Cancer | Centro de Pesquisa Clínica Natal, Rio Grande do Norte | |
| Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner Curitiba, Paraná | |
| Litavniece Dzintra practice in urology and oncological chem. Liepāja, | |
| London Health Sciences Centre London, Ontario | |
| Ltd "EVIMED" Chelyabinsk, | |
| Luz Saude | Hospital da Luz Lisboa - Centro de Investigacao Clinica Lisbon, | |
| Masarykuv onkologicky ustav Brno, | |
| Massachusetts General Hospital Boston, Massachusetts | |
| Mazowiecki Szpital Onkologiczny Waliszew, | |
| Medical Center "Avicenna" Novosibirsk, | |
| Medical Center Kalimat Sofia, | |
| Medizinische Fakultät der Otto-von-Guericke Universität Magdeburg, Saxony-Anhalt | |
| Mid Yorkshire Teaching NHS Trust¦Pinderfields Hospital - Oncology Wakefield, West Yorkshire | |
| MidLantic Urology - Bala Cynwyd Bala-Cynwyd, Pennsylvania | |
| Mie University Hospital Tsu, Mie-ken | |
| Mikkelin keskussairaala Mikkeli, | |
| Minsk City Clinical Oncological Dispensary - Oncology Department Minsk, | |
| Montefiore Einstein Center for Cancer Care The Bronx, New York | |
| Moscow Scient. Res. Institute of Oncology n.a P.A. Hertzen Moscow, | |
| Multi-Field Clinical Medical Center "Medical City" Tyumen, | |
| Municipal Non-commercial Enterprise 'City Clinical Hospital #4' of Dnipro City Council - City ?hemotherapy ?enter Dnipro, | |
| N.N. Alexandrov National Cancer Centre of Belarus - Oncology Department Lesnoy, | |
| NHS Greater Glasgow & Clyde | Beatson West of Scotland Cancer Centre - Clinical Research Unit Glasgow, | |
| NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School Nanjing, Jiangsu | |
| Nagasaki University Hospital Nagasaki, Nagasaki | |
| Nagoya University Hospital Nagoya, Aichi-ken | |
| Nantong Tumor Hospital Nantong, | |
| National Cancer Center Hospital East Kashiwa, Chiba | |
| National Cancer Institute Rio de Janeiro, | |
| National Hospital Organization Kumamoto Medical Center Kumamoto, | |
| National Hospital Organization Mito Medical Center Higashiibaraki-gun, | |
| National Hospital Organization Shinshu Ueda Medical Center Ueda, Nagano | |
| National Medical Research Radiology Center Obninsk, | |
| National Taiwan University Hospital Taipei, | |
| Nederlands Kanker Instituut Amsterdam, | |
| Nemocnice Jablonec nad Nisou Jablonec nad Nisou, | |
| New Jersey Urology - Voorhees Voorhees Township, New Jersey | |
| New Mexico Cancer Center - Albuquerque Albuquerque, New Mexico | |
| New York Cancer & Blood Specialists - Eastchester The Bronx, New York | |
| Ningbo First Hospital Ningbo, | |
| Nippon Medical School Hospital Bunkyo-ku, Tokyo | |
| Norrlands Universitetssjukhus, Umeå Umeå, | |
| Norton Cancer Institute - Downtown Louisville, Kentucky | |
| Nova Scotia Health Authority Halifax, Nova Scotia | |
| Oita University Hospital Oita, Yufu, | |
| Oncomedica S.A. Montería, Departamento de Córdoba | |
| Osaka General Medical Center Osaka, | |
| Osaka International Cancer Institute Osaka, | |
| Osaka Metropolitan University Hospital Osaka, Osaka | |
| Oulun Yliopistollinen Sairaala Oulu, | |
| P. Stradins Clinical University Hospital Riga, | |
| PI Klaipedos University Hospital Klaipėda, | |
| Parc Tauli Hospital Universitari - Oncologia Sabadell, Barcelona | |
| Peking University Third Hospital Beijing, Beijing Municipality | |
| Praxis Drs. Tim Schneider /B. Schneider Mülheim, North Rhine-Westphalia | |
| Prince Philip Hospital Llanelli, Carmarthenshire | |
| Princess Margaret Hospital-University Health Network Toronto, Ontario | |
| Privatna urologicka ambulancia, s.r.o. Trenčín, | |
| Prostate Cancer Centre Calgary, Alberta | |
| Providence Regional Cancer Partnership Everett, Washington | |
| Qilu Hosp., Shandong Univ. Jinan, Shandong | |
| Rabin Medical Center | Beilinson Hospital - Internal Medicine C Department Petah Tikva, | |
| Regional Clinical Oncology Dispensary Vladimir, | |
| Regional Medical Clinical Center of Urology and Nephrology n.a. V. I. Shapoval - Department of Oncologic Urology #5 Kharkiv, | |
| Regional communal non-profit enterprise 'Chernivtsi regional clinical hospital' - Urological department Chernivtsi, | |
| Republican Clinical Oncology Dispensary Kazan Kazan', | |
| Riga East Clinical University Hospital "Gailezers" Riga, | |
| Rostov State Medical University Rostov-on-Don, | |
| Royal Berkshire NHS Foundation Trust¦Royal Berkshire Hospital - Oncology Reading, Berkshire | |
| Ruijin Hosp. Shanghai Jiaotong Univ.School of Medicine Shanghai, | |
| Russian Oncological Scientific Center n.a. N.N. Blokhin RAMS Moscow, | |
| SE "Academician O.F. Vozianov Institute of Urology" of NAMSU - Division of Reconstructive Urology and Advanced Technologies Kyiv, | |
| SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 Rybnik, | |
| Sahlgrenska Universitetssjukhuset Gothenburg, | |
| Saiseikai Utsunomiya Hospital Utsunomiya, Tochigi | |
| Samsung Medical Center - Oncology Department Seoul, | |
| San Diego Clinical Trials San Diego, California | |
| Santa Casa de Misericórdia da Bahia Salvador, Estado de Bahia | |
| Sapporo Medical University Hospital Sapporo, Hokkaid | |
| Saratov State Medical University Saratov, | |
| Scunthorpe General Hospital Scunthorpe, North East Lincolnshire | |
| Seinäjoen keskussairaala Seinäjoki, | |
| Seoul National Univ. Bundang Hospital Seongnam-si, Gyeonggido | |
| Seoul National University Hospital Seoul, | |
| Severance Hospital, Yonsei University Health System Seoul, | |
| Sf. Nectarie Oncology Center Craiova, | |
| Shanghai General Hospital Shanghai, | |
| Shanghai Tenth People's Hospital Shanghai, | |
| Shanxi Medical University - First Hospital Taiyuan, Shanxi | |
| Shengjing Hospital of China Medical University Shenyang, | |
| Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (SAMSPH) Chengdu, | |
| Sichuan University West China Hospital Chengdu, Sichuan | |
| Sichuan University West China Hospital Chengdu, Sichuan | |
| Sihtasutus Põhja-Eesti Regionaalhaigla - Onkoloogia- ja hematoloogiakliinik Tallinn, | |
| Skånes Universitetssjukhus Malmö Malmo, | |
| Spaarne Gasthuis Haarlem, North Holland | |
| Spitalul Clinic Judetean Mures Târgu Mureş, | |
| Spitalul Clinic Judetean de Urgenta Oradea Oradea, | |
| St. Petersburg Clinical Hospital of RAS Saint Petersburg, | |
| St. Petersburg Medical University n.a. I.P. Pavlov Saint Petersburg, | |
| St. Vincent Regional Hospital - Oncology Billings, Montana | |
| Stadtisches Klinikum Braunschweig gGmbH Braunschweig, Lower Saxony | |
| Stanford Cancer Center Palo Alto Palo Alto, California | |
| Studienpraxis Urologie Nürtingen, Baden-Wurttemberg | |
| Sun Yat-sen University Cancer Center Guangzhou, Guangdong | |
| Sunnybrook Health Sciences Centre Toronto, Ontario | |
| Szpital Grochowski im. dr.med. Rafala Masztaka Warsaw, | |
| TC Saglik Bakanligi Goztepe ProfDr Suleyman Yalcin Sehir Has Istanbul, | |
| TOI Clinical Research Whittier, California | |
| Taichung Veterans General Hospital Xitun Dist., | |
| Taipei Veterans General Hospital Taipei, | |
| Tampere University Hospital, Tampereen yliopistollinen sairaala (TAYS) Tampere, | |
| Tergooi MC | Hilversum - Wetenschapsbureau Hilversum, | |
| The 2nd Affiliated Hospital of Soochow University Suzhou, Jiangsu | |
| The Affiliated Hospital of Qingdao University Qingdao, Shandong | |
| The Catholic University of Korea Seoul St. Mary's Hospital Seoul, | |
| The First Affiliated Hospital of NanChang University Nanchang, | |
| The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu | |
| The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang | |
| The First Affiliated Hospital of Xi'An Jiaotong University Xi'an, Shaanxi | |
| The First Affiliated Hospital of Xiamen University Xiamen, | |
| The First Affiliated hospital of Fujian Medical University Fuzhou, Fujian | |
| The Fraternity Memorial Hospital Sumida-ku, Tokyo | |
| The Ohio State University - Arthur G James Cancer Hospital and Richard J Solove Research Institute Columbus, Ohio | |
| The Second Hospital of Anhui medical university Hefei, Anhui | |
| The Second Hospital of Tianjin Medical University Tianjin, | |
| The University of Osaka Hospital Suita, | |
| The Urology Center of Colorado Denver, Colorado | |
| The Urology Group - Norwood Surgery Center Cincinnati, Ohio | |
| Tianjin Medical University Cancer Institute & Hospital Tianjin, | |
| TidalHealth Peninsula Regional, Inc. - Oncology Salisbury, Maryland | |
| Toho University Sakura Medical Center Sakura, Chiba | |
| Tokyo Metropolitan Institute for Geriatrics and Gerontology Itabashi-ku, Tokyo | |
| Tokyo Metropolitan Police Hospital Nakano-ku, Tokyo | |
| Tolna Varmegyei Balassa Janos Korhaz Szekszárd, | |
| Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech. Wuhan, Hubei | |
| Tottori University Hospital Yonago, | |
| Tower Urology Los Angeles, California | |
| Toyama University Hospital Toyama, | |
| Turun Yliopistollinen keskussairaala Turku, | |
| Turun Yliopistollinen keskussairaala Turku, | |
| ULSM - Hospital Pedro Hispano Matosinhos Municipality, Porto District | |
| URMC Wilmot Cancer Center Rochester, New York | |
| UZ Gent Ghent, | |
| Unidade Local de Saude Almada-Seixal | Hospital Garcia de Orta - Research Department Almada, Setúbal District | |
| Uniklinik Tübingen / Urologie Tübingen, Baden-Wurttemberg | |
| Universitatsklinikum Freiburg Freiburg im Breisgau, | |
| University College London Hospitals NHS Foundation Trust London, | |
| University of Electronic Science & Technology of China - Sichuan Cancer Hospital & Institute (Sichuan Provincial Tumor Hospital) Chengdu, | |
| University of Miyazaki Hospital Miyazaki, | |
| University of Pretoria, Clinical Research Unit Pretoria, Gauteng | |
| Universitätsklinikum AKH Wien Vienna, | |
| Universitätsklinikum Erlangen Erlangen, | |
| Universitätsklinikum Münster Münster, | |
| Universitätsklinikum Ulm Ulm, | |
| Universitätsklinikum der Johann Wolfgang Goethe Universität Frankfurt am Main, Hesse | |
| Universitätsmedizin der Johannes Gutenberg Universität Mainz Mainz, | |
| Uniwersyteckie Centrum Kliniczne Gdansk, | |
| União Bras. de Edu. e Assist. Hospital São Lucas da PUCRS Porto Alegre, Rio Grande do Sul | |
| Uro-Gyn-Zentrum Wall Hr. Dr. Jochen Gleißner Wuppertal, North Rhine-Westphalia | |
| Urocentrum Praha, s.r.o. Prague, | |
| Urologica Praktyka Lekarska Adam Marcheluk Siedlce, | |
| Urologische GemPraxis Dr. R. Rudolph Kirchheim unter Teck, Baden-Wurttemberg | |
| Urologische Gemeinschaftspraxis Carl-Andreas-Meilinger Emmendingen, Baden-Wurttemberg | |
| Urologische Gemeinschaftspraxis Dr. Simone Maier Reutlingen, Baden-Wurttemberg | |
| Urologische Gemeinschaftspraxis Muehlacker Mühlacker, Baden-Wurttemberg | |
| Urology Associates, PC Nashville, Tennessee | |
| Urology Cancer Center, PC Omaha, Nebraska | |
| Urology Centers of Alabama, PC Homewood, Alabama | |
| Urology Clinics of North Texas Dallas, Texas | |
| VA Eastern Colorado Health Care System Aurora, Colorado | |
| VA Greater Los Angeles Healthcare System Los Angeles, California | |
| Vidzemes Hospital Valmiera, | |
| Vilnius University Hospital Santaros Klinikos Vilnius, | |
| Virginia Commonwealth University Richmond, Virginia | |
| Vseobecna Fakultni Nemocnice v Praze Prague, | |
| Wakayama Medical University Hospital Wakayama, | |
| XCancer Omaha Omaha, Nebraska | |
| Yamaguchi University Hospital Ube-Shi, Yamaguchi | |
| Yantai Yuhuangding Hospital Yantai, Shandong | |
| Yokohama City University Medical Center Kanagawa, | |
| Yokosuka Kyosai Hospital Yokosuka, Kanagawa | |
| Zakarpattia Anti-Tumor Centre - Chemotherapy Department Uzhhorod, | |
| Zala Varmegyei Szent Rafael Korhaz Zalaegerszeg, | |
| Zhejiang Provincial People's Hospital Hangzhou, | |
| Zhejiang Provincial People's Hospital Hangzhou, | |
| Zhongshan Hospital, Fudan University - Oncology Department Shanghai, | |
| Zuyderland Medical Centre | Internal Medicine Department Geleen, | |
| the First Hospital of Jilin University Changchun, Jilin |
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Iovance Biotherapeutics Study Team lungcelltherapy.com - Clinical.Inquiries@iovance.com
Poklepovic, Andrew, S
NCT04614103
HM20023194
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients who are over 70 years of age may be allowed to enroll after discussion with the Medical Monitor.
* Have historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS1 genomic alterations.
* For patients who have actionable mutations (other than EGFR, ALK, or ROS1 genomic alterations), 1 additional line of therapy with the appropriate health authority approved targeted therapy is required.
* Patients must have documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy ± bevacizumab. No more than 1 prior line is allowed if ICI and platinum-based chemotherapy were administered concurrently and no more than 2 prior lines are allowed for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines.
* LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination and meet all eligibility criteria except documented disease progression. These patients must intend to receive TIL therapy after disease progression
* Prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy.
* At least 1 resectable lesion for TIL production and at least one remaining measurable lesion, as defined by RECIST v1.1
* Have adequate organ function
* LVEF \> 45%, NYHA Class 1
* Have adequate pulmonary function
* ECOG performance status of 0 or 1
* Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy
Exclusion Criteria:
* Patients who have EGFR, ALK or ROS1 driver mutations
* Patients who have symptomatic, untreated brain metastases.
* Patients who have had allogeneic organ transplant or prior cell therapy within the past 20 years
* Patients who have any form of primary immunodeficiency
* Patients who are on systemic steroid therapy ≥ 10 mg/day of prednisone or equivalent.
* Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment
* Patients who have had another primary malignancy within the previous 3 years
* Participation in another interventional clinical study within 21 days BIOLOGICAL: LN-145, BIOLOGICAL: LN-145
Metastatic Non Small Cell Lung Cancer
LN-145, Cell Therapy, Autologous Adoptive Cell Therapy, Cellular Immuno-therapy, Tumor Infiltrating Lymphocytes, TIL, IL-2, Non Small Cell Lung Cancer, NSCLC, Second line Lung Cancer, Bronchial Neoplasms, Carcinoma, Lung Disease, Metastatic Lung Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic NSCLC, Lung Carcinoma, PD-L1, Stage IV Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV NSCLC, Systemic Therapy, 2nd line therapy, Second line therapy, CPI, Immune checkpoint inhibitor (ICI), NSCLC Recurrent, Recurrent Lung Cancer, Recurrent Lung Carcinoma
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 84 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AdventHealth Cancer Institute Orlando, Florida | |
| Advocate Aurora Health Park Ridge, Illinois | |
| Allegheny General Hospital Pittsburgh, Pennsylvania | |
| Atrium Health Wake Forest University Health Sciences Winston-Salem, North Carolina | |
| Augusta University Augusta, Georgia | |
| Avera Medical Group Cancer Institute Sioux Falls, South Dakota | |
| Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro, | |
| Azienda Ospedaliera Universitaria Careggi Florence, Tuscany | |
| Baptist Cancer Center Memphis, Tennessee | |
| C.H. Regional Reina Sofia Córdoba, | |
| CHU Nantes Nantes, | |
| Centre Hospitalier Lyon Sud Pierre-Bénite, | |
| Centre Hospitalier Universitaire Vaudois Lausanne Lausanne, Canton of Vaud | |
| Centre Hospitalier de L'Universite de Montreal (CHUM) Montreal, Quebec | |
| Christiana Care Health System Newark, Delaware | |
| City of Hope Duarte, California | |
| Clinical Universitaria de Navarra Pamplona, | |
| Consorcio Hospital General Universitario de Valencia Valencia, | |
| Dana Farber Cancer Institute Boston, Massachusetts | |
| Fox Chase Cancer Center Philadelphia, Pennsylvania | |
| Gachon Unversity Gil Medical Center Incheon, | |
| Guy's Hospital Great Maze Pond, | |
| H Lee Moffitt Cancer Center and Research Institute Tampa, Florida | |
| Henry Ford Health System Detroit, Michigan | |
| Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis Amsterdam, | |
| Hollywood Private Hospital Ramsay Nedlands, Western Australia | |
| Hospital Clinic de Barcelona Barcelona, | |
| Hospital Clinico Universitario de Valencia Valencia, | |
| Hospital Regional Universitario de Malaga Málaga, | |
| Hospital Universitario 12 de Octubre Madrid, | |
| Hospital Universitario A Coruna A Coruña, LA Coruna | |
| Hospital Universitario La Paz Madrid, | |
| Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal Madrid, | |
| Hospital Universitario Ramon y Cajal Madrid, | |
| Hospital Universitario Virgen del Rocio Seville, | |
| Houston Methodist Houston, Texas | |
| IRCCS Fondazione del Piemonte per l'Oncologia Piemonte, | |
| Icahn School of Medicine at Mount Sinai New York, New York | |
| Institut Paoli Calmettes Marseille, | |
| Instituto Oncologico Rosell Barcelona, | |
| Karmanos Cancer Institute Detroit, Michigan | |
| MD Anderson Cooper Camden, New Jersey | |
| Memorial Sloan Kettering Cancer Center New York, New York | |
| National Cancer Centre Singapore Singapore, | |
| New York University Langone Medical Center New York, New York | |
| Novant Health - Charlotte Charlotte, North Carolina | |
| Novant Health - Winston-Salem Winston-Salem, North Carolina | |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | |
| Oregon Health and Science University Portland, Oregon | |
| Princess Margaret Cancer Centre Toronto, Ontario | |
| Roswell Park Cancer Institute Buffalo, New York | |
| Royal Marsden Hospital London, | |
| Rush University Medical Center Chicago, Illinois | |
| Samsung Medical Center Seoul, | |
| Sanford Cancer Center Sioux Falls, South Dakota | |
| Sanford Roger Maris Cancer Center Fargo, North Dakota | |
| Sarah Cannon Research Institute Nashville, Tennessee | |
| Seattle Cancer Care Alliance Seattle, Washington | |
| Severance Hospital, Yonsei University Seoul, | |
| St. Vincent's Hospital Melbourne, Victoria | |
| Sylvester Comprehensive Cancer Center Miami, Florida | |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas, Texas | |
| The Christie NHS Foundation Trust Manchester, | |
| UC San Diego Moores Cancer Center La Jolla, California | |
| Universitatsklinikum Bonn Bonn, | |
| Universitatsklinikum Mannheim Mannheim, | |
| University College London London, | |
| University Hospital of Zurich/ Universitätsspital Zürich Zurich, | |
| University of Cincinnati Medical Center Cincinnati, Ohio | |
| University of Florida Health Cancer Center Orlando, Florida | |
| University of Illinois Hospital & Health Sciences System Chicago, Illinois | |
| University of Kentucky-Markey Cancer Center Lexington, Kentucky | |
| University of Louisville Louisville, Kentucky | |
| University of Maryland Baltimore, Maryland | |
| University of Minnesota Minneapolis, Minnesota | |
| University of Nebraska Medical Center Omaha, Nebraska | |
| University of North Carolina Chapel Hill, North Carolina | |
| University of Oklahoma Oklahoma City, Oklahoma | |
| University of Rochester Medical Center Rochester, New York | |
| University of Southern California Los Angeles, California | |
| University of Tennessee Medical Center Knoxville, Tennessee | |
| Universitätsklinikum Carl Gustav Carus, MK I Dresden, | |
| VCU Medical Center (Virginia Commonwealth University) Richmond, Virginia | |
| Westmead Hospital Sydney, New South Wales |
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Sherry Boyett, RN - sherry.boyett@vcuhealth.org
NCT05424003
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Male or female age 18-75 years who received LT for any indication (i.e. NASH, hepatitis C, alcohol-induced cirrhosis, autoimmune hepatitis, etc.)
* Liver transplant surgery within 8-24 weeks prior to randomization
* Fasting glucose \> 125 mg/dL or presence of diabetes (HbA1c≥6.5% or use of diabetes medications) or pre-diabetes (HbA1c \>5.7%)
* Ability to provide informed consent
* Discharged from the hospital following LT surgery
* Tolerating diet
* Normal graft function\* (determined by treating hepatologist/surgeon based on clinical status and hepatic panel)
* Stable immunosuppression according the VCU (Virginia Commonwealth University) post-LT protocols \*\* (i.e. calcineurin inhibitors + mycophenolate)
* Eligible female patients will be (1) non-pregnant, evidenced by a negative urine pregnancy test, (2) non-lactating, (3)surgically sterile or post-menopausal, or they will agree to continue to use an accepted method of birth control during the study
Exclusion Criteria:
* BMI≤ 27kg/m2
* GFR (Glomerular Filtration Rate) ≤ 25 ml/min/1.73m2
* Type 1 autoimmune diabetes (by anti-GAD (glutamic acid decarboxylase) or history of ketoacidosis)
* History of gastroparesis
* Familial or personal history of medullary thyroid cancer or MEN (Multiple Endocrine Neoplasia) 2
* History of pancreatitis
* History of active malignancy post- LT with the exception of non-melanoma skin cancers
* History of uncontrolled or unstable diabetic retinopathy or maculopathy
* Acute cellular rejection
* Hepatic artery thrombosis
* Medical non-compliance
* Active treatment with GLP (glucagon-like peptide)-1RA (receptor agonist) or SGLT (sodium-glucose cotransporter)-2 inhibitors at time of screening
* History of hypersensitivity to semaglutide or its excipients
* Women who are nursing, pregnant, or planning to become pregnant during the study, or are not using adequate contraceptive measures DRUG: Semaglutide Pen Injector, DRUG: Placebo
NAFLD
Liver Transplant
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia |
Transspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia (SCIMS Main)
Ashraf Gorgey, MPT, PhD, FACSM, FACRM - Ashraf.Gorgey@va.gov
NCT05423600
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• A written clearance from the study medical doctor to ensure that the participant is safely able to engage in the study.
• Participants must have a companion that will be able to help him/her throughout the study.
• Greater than 1-year post SCI, neurologic level of C8 or above.
• American Spinal Injury Association Impairment Scale (AIS) scores of B, C, or D indicating presence of an incomplete SCI.
• Visible muscle contraction response to NMES wrist extensors, bilaterally.
• Agreement to use telehealth services for delivery of research exercise training by study staff. Possesses appropriate technology to engage in telehealth including a personal web camera, computer, microphone, speakers, and high-speed broadband internet connection, valid email address (needed to obtain VA issued video conferencing software), and telephone number used to obtain login credentials for the In-Home Video Software - Cisco Jabber Video for Telepresence Software.
• Response of muscle contraction of wrist extensors bilaterally to neuromuscular electrical stimulation.
Exclusion Criteria:
• Unhealed fracture in upper or lower extremities.
• Severe scoliosis, severe upper extremity contractures, or other musculoskeletal issues that would impede participation in a BES + TS intervention or valid evaluation of outcome measures.
• High resting blood pressure greater than 140/80 mmHg.
• Taking anti-coagulants or anti-platelet agents, including aspirin if unable to be off this medication for medical reasons.
• Pregnancy (female participants). A home pregnancy test will be conducted to role out any pregnancy before the study at the McGuire VAMC. The test will be repeated every month during the course of the study.
• Implanted pacemakers and/or implanted defibrillator devices.
• Other exclusion criteria may include the presence of implanted electrical device, cancer, thrombosis, pacemaker, defibrillator, or seizures. Patients who are currently on or receive anti-platelet or anticoagulant medications will be excluded from the trial.
• Any condition that, in the judgment of the principal investigator or medical provider, precludes safe participation in the study.
• Other exclusion criteria at the discretion of the medical team may include:
• Uncontrolled autonomic dysreflexia (AD), refers to episodes of AD that do not respond to medications to ensure stable blood pressure in persons with SCI
• Concurrent severe neurological injuries other than SCI: MS, CP, severe TBI, and stroke.
• Unresolved deep vein thrombosis.
• Psychiatric or cognitive impairments that preclude adherence to the intervention.
• Known cardiac pathology that precludes safe participation.
• Metabolic conditions such as cardiovascular disease, uncontrolled type II diabetes mellitus, uncontrolled hypertension, and those on insulin.
• Presence of pressure sores stage three or greater.
• Presence of a symptomatic urinary tract infection.
• Severe spasticity as assessed by the Modified Ashworth Scale.
• Changing neurologic status due to conditions such as progressive posttraumatic syringomyelia.
PROCEDURE: BES + TS, PROCEDURE: Experimental: BES+sham TS
Tetraplegia/Tetraparesis
Spinal Cord Injury
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 3 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Richmond VA Medical Center Richmond, Virginia | |
| Sheltering Arms Physical Rehabilitation Centers Richmond, Virginia | |
| Virginia Commonwealth University Richmond, Virginia |
Children's Bipolar Network Treatment Trial I (CBN)
David J Miklowitz, PhD - dmiklowitz@mednet.ucla.edu
NCT05427123
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Youth 9-19 years old
* Youth diagnosed with Bipolar disorder (I, II, Other Specified) or Cyclothymic Disorder by the study team during the diagnostic interview screening
* Youth is able to read and communicate in English to the degree necessary to be able to assent and participate (with help) in their treatment and assessments appropriate for ages 9 and up
* Youth has a caregiver able to participate in ongoing basis in assessment and treatment
* The participating caregiver can reliably read and communicate in English for purposes of study consenting, assessment, and treatment, unless preferred language translation services are regularly available.
Exclusion Criteria:
* Youth has DSM-5 diagnosis of autism spectrum disorder
* Youth has DSM-5 diagnosis of substance or alcohol abuse with impairment within 3 mos.
* Youth has a medical or psychiatric disorder that is life-threatening or requires immediate hospitalization or emergency medical or therapeutic treatment
* Evidence of recent sexual or physical abuse of the youth by legally responsible caregivers
* Evidence of recent intimate partner violence between caregivers responsible for the youth's care OTHER: Medication or psychosocial treatment
Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Other Specified Bipolar and Related Disorder, Mood Instability, Child Mental Disorder, Adolescent - Emotional Problem
medication, psychosocial, treatment, longitudinal, naturalistic, assessment
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 4 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| University of California, Los Angeles, Max Gray Child and Adolescent Mood Disorders Program (CHAMP) Los Angeles, California | David J Miklowitz, PhD - (dmiklowitz@mednet.ucla.edu) Megan C Ichinose, PhD - (michinose@mednet.ucla.edu) |
| University of Colorado Anschutz Medical Campus, Helen and Arthur E. Johnson Depression Center Aurora, Colorado | |
| University of Pittsburgh Child and Adolescent Bipolar Spectrum Services Clinic (CABS) Pittsburgh, Pennsylvania | |
| Virginia Commonwealth University Medical Center Richmond, Virginia |
GiST (GiST)
Vences, Karina - venceskm@vcu.edu
Goldman, Myla
NOT REQUIRED
HM20022775
Diseases of Nervous System and Sense Organs (320-389)
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Vences, Karina - (venceskm@vcu.edu) |
Uptake of NCI Research Tested Intervention Program to Increase CRC Screening in Rural Setting
Preston, Michael - prestonm2@vcu.edu
Preston, Michael
16928
HM20019703
Rectum, Colon
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Preston, Michael - (prestonm2@vcu.edu) |
Community Outreach and Engagement Key Informant Interviews
Cummings, Yvonne - yvonne.cummings@vcuhealth.org
Sheppard, Vanessa, B.
15900
HM20018062
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Cummings, Yvonne - (yvonne.cummings@vcuhealth.org) |
A Cognitive Task Analysis of Pediatric Hematology/Oncology Faculty
DiazGranados, Deborah - diazgranados@vcu.edu
Helou, Marieka, Ann
15801
HM20017417
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | DiazGranados, Deborah - (diazgranados@vcu.edu) |
CASTOR-2: Identifying Subclinical Cardiotoxicity Following RT for Locally Advanced Lung Cancer (CASTOR-2)
Kontos, Emily - kontosej@vcu.edu
Thomas, Georgia
15564
HM20017432
Lung
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Kontos, Emily - (kontosej@vcu.edu) |
Killer Immunoglobulin-Like Receptor Interactions to Optimize Natural Killer Cell Function in SCT
Roberts, Catherine, H. - croberts2@vcu.edu
Toor, Amir, A
15122
HM20016672
Other Hematopoietic
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Roberts, Catherine, H. - (croberts2@vcu.edu) |
Biomarkers of Malignant and Non-Malignant Pleural Effusion
Narron, Kyle, A - Kyle.Narron@vcuhealth.org
Shojaee, Samira
15081
HM20012669
Any Site
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Narron, Kyle, A - (Kyle.Narron@vcuhealth.org) |
Acceptability and Efficacy of Enterade in Children at Risk for Environmental Enteric Dysfunction
Minter, Sabrina - sabrina.minter@vcuhealth.org
Donowitz, Jeffrey
NCT05291559
HM20023567
Infectious and Parasitic Diseases (001-139)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Minter, Sabrina - (sabrina.minter@vcuhealth.org) |
HEALEY ALS Platform Trial - REGIMEN E
Smith, LaVon - lavon.smith@vcuhealth.org
Gwathmey, Kelly
NCT05136885
HM20022250E
drug: Trehalose
Diseases of Nervous System and Sense Organs (320-389)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Smith, LaVon - (lavon.smith@vcuhealth.org) |
OL Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV Generalized MG (ADAPT NXT) (ADAPT NXT)
Wilkins, Bridget - bridget.wilkins@vcuhealth.org
Gwathmey, Kelly
NCT04980495
HM20023221
drug: Argx-113
Diseases of Nervous System and Sense Organs (320-389)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Wilkins, Bridget - (bridget.wilkins@vcuhealth.org) |
ASCEND - Post-Market Follow-Up - Patients Treated with On-X Ascending Aortic Prosthesis
Han, Jinfeng - jinfeng.han@vcuhealth.org
Quader, Mohammed
NCT05082454
HM20023997
Modality: No vcuhs billing
Diseases of Circulatory System (390-459)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Han, Jinfeng - (jinfeng.han@vcuhealth.org) |
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH (Symmetry)
Lester Scholtes, Rebecca - Rebecca.Lester@vcuhealth.org
Asgharpour, Amon
NCT05039450
HM20023488
drug: Efruxifermin
Diseases of Digestive System (520-579)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Lester Scholtes, Rebecca - (Rebecca.Lester@vcuhealth.org) |
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) (MK3475-C93)
Toll Free Number - Trialsites@merck.com
Miller, Devin, T
NCT05173987
HM20023914
Show full eligibility criteria
Hide eligibility criteria
The main inclusion and exclusion criteria include but are not limited to the following:
• Has a histologically confirmed diagnosis of inoperable, Stage III or IV or recurrent Endometrial Carcinoma (EC) or carcinosarcoma (mixed Mullerian tumor) that is centrally confirmed as dMMR
• Has received no prior systemic therapy for EC except for the following:
• May have received prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease
• May have received prior hormonal therapy for treatment of EC, provided that it was discontinued ≥1 week prior to randomization
• Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.
• Is not pregnant or breastfeeding and agrees to not donate eggs and use a highly effective contraceptive method for 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapy if a woman of childbearing potential (WOCBP)
• Has a negative highly sensitive pregnancy test (urine or serum) within 24 hours for urine or 72 hours for serum before the first dose of study intervention if a WOCBP
• Provides an archival tumor tissue sample or newly obtained (core, incisional, or excisional) biopsy of a tumor lesion not previously irradiated for verification of dMMR status and histology
• Is Hepatitis B surface antigen (HBsAg) positive but has received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load prior to randomization
• Has a history of Hepatitis C virus (HCV) infection but has undetectable HCV viral load at screening.
• Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas and neuroendocrine tumors are not allowed
• Has EC of any histology that is proficient mismatch repair (pMMR)
• Is a candidate for curative-intent surgery or curative-intent radiotherapy
• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137])
• Has received prior systemic anticancer therapy including investigational agents for EC. This includes any chemotherapy given for EC other than as a radiosensitizer
• Has had a major operation and has not recovered adequately from the procedure and/or any complications from the operation before starting study intervention
• Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed
• Is currently participating in or has participated in a study of an investigational agent for EC, has participated in a study of an investigational agent for non-EC within 4 weeks before the first dose of study intervention, or has used an investigational device within 4 weeks before the first dose of study intervention
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding carcinoma in situ of the bladder) that have undergone potentially curative therapy are not excluded
• Has known active CNS metastases and/or carcinomatous meningitis
• Has a known intolerance to any study intervention and/or any of its excipients
• Has an active autoimmune disease that has required systemic treatment in past 2 years
• Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• Has an active infection, requiring systemic therapy
• Has a known history of human immunodeficiency virus (HIV) infection
• Has had an allogenic tissue/solid organ transplant
Inclusion Criteria:
• Has a histologically confirmed diagnosis of inoperable, Stage III or IV or recurrent Endometrial Carcinoma (EC) or carcinosarcoma (mixed Mullerian tumor) that is centrally confirmed as dMMR
• Has received no prior systemic therapy for EC except for the following:
• May have received prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease
• May have received prior hormonal therapy for treatment of EC, provided that it was discontinued ≥1 week prior to randomization
• Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before randomization.
• Is not pregnant or breastfeeding and agrees to not donate eggs and use a highly effective contraceptive method for 120 days after the last dose of pembrolizumab or 180 days after the last dose of chemotherapy if a woman of childbearing potential (WOCBP)
• Has a negative highly sensitive pregnancy test (urine or serum) within 24 hours for urine or 72 hours for serum before the first dose of study intervention if a WOCBP
• Provides an archival tumor tissue sample or newly obtained (core, incisional, or excisional) biopsy of a tumor lesion not previously irradiated for verification of dMMR status and histology
• Is Hepatitis B surface antigen (HBsAg) positive but has received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load prior to randomization
• Has a history of Hepatitis C virus (HCV) infection but has undetectable HCV viral load at screening.
Exclusion Criteria:
• Has uterine mesenchymal tumor such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas. Adenosarcomas and neuroendocrine tumors are not allowed
• Has EC of any histology that is proficient mismatch repair (pMMR)
• Is a candidate for curative-intent surgery or curative-intent radiotherapy
• Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137])
• Has received prior systemic anticancer therapy including investigational agents for EC. This includes any chemotherapy given for EC other than as a radiosensitizer
• Has had a major operation and has not recovered adequately from the procedure and/or any complications from the operation before starting study intervention
• Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed
• Is currently participating in or has participated in a study of an investigational agent for EC, has participated in a study of an investigational agent for non-EC within 4 weeks before the first dose of study intervention, or has used an investigational device within 4 weeks before the first dose of study intervention
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (excluding carcinoma in situ of the bladder) that have undergone potentially curative therapy are not excluded
• Has known active CNS metastases and/or carcinomatous meningitis
• Has a known intolerance to any study intervention and/or any of its excipients
• Has an active autoimmune disease that has required systemic treatment in past 2 years
• Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• Has an active infection, requiring systemic therapy
• Has a known history of human immunodeficiency virus (HIV) infection
• Has had an allogenic tissue/solid organ transplant
Biological: pembrolizumab, Drug: carboplatin, Drug: paclitaxel, Drug: docetaxel, Drug: cisplatin
Endometrial Neoplasms
Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 182 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AHN West Penn Hospital ( Site 0011) Pittsburgh, Pennsylvania | Study Coordinator |
| AULSS8 Berica-Ospedale S.Bortolo-ONCOLOGIA CLINICA ( Site 1510) Vicenza, Veneto | Study Coordinator |
| Aalborg Universitetshospital, Syd ( Site 0905) Aalborg, Nordjylland | Study Coordinator |
| Affiliated Hospital of Guangdong Medical College ( Site 0731) Zhanjiang, Guangdong | Study Coordinator |
| Akdeniz Universitesi Hastanesi ( Site 2701) Antalya, | Study Coordinator |
| Amsterdam UMC, locatie AMC ( Site 1706) Amsterdam, Noord-Holland | Study Coordinator |
| Anhui Provincial Hospital-Obstetrics and Gynecology ( Site 0730) Hefei, Anhui | Study Coordinator |
| Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 2303) Seoul, | Study Coordinator |
| Asplundh Cancer Pavilion ( Site 0014) Willow Grove, Pennsylvania | Study Coordinator |
| Auckland City Hospital-Cancer & Blood Research ( Site 1801) Auckland, | Study Coordinator |
| Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1509) Firenze, Toscana | Study Coordinator |
| BC Cancer Kelowna ( Site 0517) Kelowna, British Columbia | Study Coordinator |
| BC Cancer Vancouver-Clinical Trials Unit ( Site 0518) Vancouver, British Columbia | Study Coordinator |
| Baptist Health Lexington ( Site 0042) Lexington, Kentucky | Study Coordinator |
| Beijing Cancer hospital ( Site 0715) Beijing, Beijing | Study Coordinator |
| Beijing Obstetric and Gynecology Hospital ( Site 0740) Beijing, Beijing | Study Coordinator |
| Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2003) Bialystok, Podlaskie | Study Coordinator |
| Binzhou Medical University Hospital-Oncology department ( Site 0735) Binzhou, Shandong | Study Coordinator |
| Bon Secours Cork Hospital ( Site 1305) Cork, | Study Coordinator |
| CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2405) A Coruña, La Coruna | Study Coordinator |
| COMPLEJO HOSPITALARIO DE NAVARRA ( Site 2407) Pamplona, Navarra | Study Coordinator |
| Cancer Hospital of Shantou University Medical College ( Site 0732) Shantou, Guangdong | Study Coordinator |
| Catharina Ziekenhuis-Oncology ( Site 1704) Eindhoven, Noord-Brabant | Study Coordinator |
| Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman ( Site 0320) Liège, Liege | Study Coordinator |
| Centre Hospitalier de l'Université de Montréal ( Site 0519) Montréal, Quebec | Study Coordinator |
| Centrum Onkologii Ziemi Lubelskiej ( Site 2006) Lublin, Lubelskie | Study Coordinator |
| Charité Campus Virchow-Klinikum ( Site 1103) Berlin, | Study Coordinator |
| Cross Cancer Institute ( Site 0513) Edmonton, Alberta | Study Coordinator |
| Edith Wolfson Medical Center-Obstetrics & Gynecology ( Site 1405) Holon, | Study Coordinator |
| Ehime University Hospital ( Site 1614) Toon, Ehime | Study Coordinator |
| Epworth Freemasons ( Site 0203) Melbourne, Victoria | Study Coordinator |
| Erasmus Medisch Centrum-Medical Oncology ( Site 1701) Rotterdam, Zuid-Holland | Study Coordinator |
| Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 0401) Praha, Praha 8 | Study Coordinator |
| Fakultni nemocnice Kralovske Vinohrady-Gynekologicko-porodnická klinika ( Site 0408) Praha 10, | Study Coordinator |
| Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0402) Olomouc, Olomoucky Kraj | Study Coordinator |
| Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 0403) Ostrava, Moravskoslezsky Kraj | Study Coordinator |
| Fakultní nemocnice Brno Bohunice-Gynekologicko-porodnicka klinika ( Site 0404) Brno, Brno-mesto | Study Coordinator |
| FirstHealth Clinical Trials ( Site 0050) Pinehurst, North Carolina | Study Coordinator |
| Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 150 Milan, Lombardia | Study Coordinator |
| Fondazione Policlinico Universitario Agostino Gemelli-Ginecologia Oncologica ( Site 1502) Roma, Lazio | Study Coordinator |
| Fujian Provincial Cancer Hospital ( Site 0720) Fuzhou, Fujian | Study Coordinator |
| Fuling Central Hospital ( Site 0733) Fulingqu, Chongqing | Study Coordinator |
| Fundación Instituto Valenciano de Oncología-Oncologico ( Site 2404) Valencia, Valenciana, Comunitat | Study Coordinator |
| Gangnam Severance Hospital ( Site 2304) Seoul, | Study Coordinator |
| Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0323) Charleroi, Hainaut | Study Coordinator |
| Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 0704) Nanning, Guangxi | Study Coordinator |
| Gunma Prefectural Cancer Center-Gynecology ( Site 1603) Ota, Gunma | Study Coordinator |
| HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2401) Sevilla, | Study Coordinator |
| Hacettepe Universite Hastaneleri-oncology hospital ( Site 2704) Ankara, | Study Coordinator |
| Hainan General Hospital ( Site 0703) Haikou, Hainan | Study Coordinator |
| Hammersmith Hospital-Medical Oncology ( Site 2808) London, London, City Of | Study Coordinator |
| Harbin Medical University Cancer Hospital ( Site 0711) Harbin, Heilongjiang | Study Coordinator |
| Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1003) Helsinki, Uusimaa | Study Coordinator |
| Henan Cancer Hospital ( Site 0713) Zhengzhou, Henan | Study Coordinator |
| Herlev and Gentofte Hospital ( Site 0902) Copenhagen, Hovedstaden | Study Coordinator |
| Hokkaido University Hospital ( Site 1601) Sapporo, Hokkaido | Study Coordinator |
| HonorHealth-USOR HonorHealth ( Site 8000) Phoenix, Arizona | Study Coordinator |
| Hospital Universitari Vall d'Hebron ( Site 2403) Barcelona, | Study Coordinator |
| Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2402) Madrid, Madrid, Comunidad De | Study Coordinator |
| Hunan Cancer Hospital ( Site 0709) Changsha, Hunan | Study Coordinator |
| IRCCS - AOU di Bologna-SSD Oncologia medica Addarii ( Site 1503) Bologna, Emilia-Romagna | Study Coordinator |
| Icahn School of Medicine at Mount Sinai ( Site 0052) New York, New York | Study Coordinator |
| Institut Jules Bordet-Medicine Oncology ( Site 0321) Bruxelles, Bruxelles-Capitale, Region De | Study Coordinator |
| Istanbul Universitesi Cerrahpasa ( Site 2702) Fatih, Istanbul | Study Coordinator |
| Istituto Europeo di Oncologia IRCCS-Divisione di Ginecologia Oncologica ( Site 1506) Milano, | Study Coordinator |
| Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 1 Napoli, Campania | Study Coordinator |
| Istituto Nazionale Tumori Regina Elena-Oncologia Medica 1 ( Site 1504) Rome, Roma | Study Coordinator |
| Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 1513) Meldola, Emilia-Romagna | Study Coordinator |
| Iwate Medical University Hospital ( Site 1602) Shiwa-gun Yahaba-cho, Iwate | Study Coordinator |
| Japanese Foundation for Cancer Research ( Site 1616) Koto, Tokyo | Study Coordinator |
| Jewish General Hospital ( Site 0504) Montreal, Quebec | Study Coordinator |
| Jiangsu Province Hospital-Oncology Department ( Site 0707) Nanjing, Jiangsu | Study Coordinator |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026) Hackensack, New Jersey | Study Coordinator |
| Kaiser Permanente Riverside Medical Center ( Site 0045) Riverside, California | Study Coordinator |
| Karmanos Cancer Institute ( Site 0029) Detroit, Michigan | Study Coordinator |
| Karolinska Universitetssjukhuset Solna ( Site 2502) Solna, Stockholms Lan | Study Coordinator |
| Keio university hospital ( Site 1606) Shinjyuku-ku, Tokyo | Study Coordinator |
| Kuopion Yliopistollinen Sairaala ( Site 1002) Kuopio, Pohjois-Savo | Study Coordinator |
| Kurume University Hospital ( Site 1612) Kurume, Fukuoka | Study Coordinator |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0016) New York, New York | Study Coordinator |
| Leids Universitair Medisch Centrum-Medical Oncology ( Site 1702) Leiden, Zuid-Holland | Study Coordinator |
| Maastricht UMC+ ( Site 1709) Maastricht, Limburg | Study Coordinator |
| Mackay Memorial Hospital ( Site 2601) Taipei, | Study Coordinator |
| Maryland Oncology Hematology, P.A.-USOR Maryland Oncology Hematology, P.A. ( Site 8002) Rockville, Maryland | Study Coordinator |
| Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2007) Siedlce, Mazowieckie | Study Coordinator |
| McGill University Health Centre ( Site 0505) Montréal, Quebec | Study Coordinator |
| Memorial Sloan Kettering Cancer Center ( Site 0009) New York, New York | Study Coordinator |
| Midwestern Regional Medical Center,Inc. DBA CTCA, Chicago ( Site 0003) Zion, Illinois | Study Coordinator |
| Monash Health ( Site 0202) Clayton, Victoria | Study Coordinator |
| Moores Cancer Center ( Site 0037) La Jolla, California | Study Coordinator |
| Moscow City Oncology Hospital #62 ( Site 2204) Krasnogorsk, Moskovskaya Oblast | |
| Mount Sinai Cancer Center ( Site 0018) Miami Beach, Florida | Study Coordinator |
| NATIONAL CHENG-KUNG UNI. HOSP. ( Site 2604) Tainan, | Study Coordinator |
| Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 20 Gliwice, Slaskie | Study Coordinator |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit Warszawa, Mazowieckie | Study Coordinator |
| National Cancer Center Hospital ( Site 1607) Chuo-ku, Tokyo | Study Coordinator |
| National Cancer Center Hospital East ( Site 1604) Kashiwa, Chiba | Study Coordinator |
| National Hospital Organization Kyushu Cancer Center ( Site 1608) Fukuoka, | Study Coordinator |
| National Hospital Organization Shikoku Cancer Center ( Site 1611) Matsuyama, Ehime | Study Coordinator |
| National Taiwan University Hospital ( Site 2603) Taipei, | Study Coordinator |
| Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 0406) Nový Jiín, Novy Jicin | Study Coordinator |
| Nemocnice Tomase Bati ve Zline-Onkologické oddělení ( Site 0407) Zlín, Zlinsky Kraj | Study Coordinator |
| Niigata University Medical & Dental Hospital ( Site 1613) Chuo-ku, Niigata, Niigata | Study Coordinator |
| Norrlands universitetssjukhus-Cancercentrum ( Site 2503) Umeå, Vasterbottens Lan | Study Coordinator |
| Northern Cancer Institute ( Site 0206) St Leonards, New South Wales | Study Coordinator |
| Northside Hospital ( Site 0017) Atlanta, Georgia | Study Coordinator |
| Obstetrics & Gynecology Hospital of Fudan University ( Site 0702) Shanghai, Shanghai | Study Coordinator |
| Országos Onkológiai Intézet-Ngyógyászat ( Site 1201) Budapest, Pest | Study Coordinator |
| Oslo universitetssykehus, Radiumhospitalet ( Site 1901) Oslo, | Study Coordinator |
| Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 1514) Torino, Piemonte | Study Coordinator |
| Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0207) Melbourne, Victoria | Study Coordinator |
| Princess Margaret Cancer Centre ( Site 0510) Toronto, Ontario | Study Coordinator |
| Providence Portland Medical Center ( Site 0031) Portland, Oregon | Study Coordinator |
| ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2806) London, London, City Of | Study Coordinator |
| Radboudumc-Medical Oncology ( Site 1703) Nijmegen, Gelderland | Study Coordinator |
| Rambam Health Care Campus-Gyneco-oncology unit ( Site 1402) Haifa, | Study Coordinator |
| Rigshospitalet ( Site 0903) Copenhagen, Hovedstaden | Study Coordinator |
| Roskilde Sygehus-Oncology department ( Site 0904) Roskilde, Sjaelland | Study Coordinator |
| Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si Brisbane, Queensland | Study Coordinator |
| SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 0710) Guangzhou, Guangdong | Study Coordinator |
| Saitama Medical University International Medical Center ( Site 1605) Hidaka-shi, Saitama | Study Coordinator |
| Sanford Cancer Center-Gynecologic Oncology ( Site 0002) Sioux Falls, South Dakota | Study Coordinator |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0055) Fargo, North Dakota | Study Coordinator |
| Sanford Medical Center ( Site 0054) Bismarck, North Dakota | Study Coordinator |
| Sarasota Memorial Hospital ( Site 0005) Sarasota, Florida | Study Coordinator |
| Saskatoon Cancer Center-Clinical Research Department ( Site 0520) Saskatoon, Saskatchewan | Study Coordinator |
| Seoul National University Hospital ( Site 2302) Seoul, | Study Coordinator |
| Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 2301) Seoul, | Study Coordinator |
| Shaanxi Provincial Cancer Hospital ( Site 0714) XI An, Shaanxi | Study Coordinator |
| Shaare Zedek Medical Center ( Site 1404) Jerusalem, | Study Coordinator |
| Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 0717) Shanghai, Shanghai | Study Coordinator |
| Sheba Medical Center ( Site 1401) Ramat Gan, | Study Coordinator |
| Shizuoka Cancer Center ( Site 1609) Nagaizumi-cho,Sunto-gun, Shizuoka | Study Coordinator |
| Sidney Kimmel Cancer Center - Jefferson Health ( Site 0053) Philadelphia, Pennsylvania | Study Coordinator |
| Skånes Universitetssjukhus Lund-Department of Hematology ( Site 2504) Lund, Skane Lan | Study Coordinator |
| Soroka Medical Center ( Site 1403) Be'er Sheva, | Study Coordinator |
| Southeastern Regional Medical Center ( Site 0046) Newnan, Georgia | Study Coordinator |
| Southwest Hospital of Third Military Medical University ( Site 0719) Chongqing, Chongqing | Study Coordinator |
| St Bartholomew's Hospital ( Site 2804) London, England | Study Coordinator |
| St. Dominic's Hospital ( Site 0024) Jackson, Mississippi | Study Coordinator |
| St. James's Hospital-Cancer clinical trials office ( Site 1301) Dublin, | Study Coordinator |
| St. John of God Subiaco Hospital-Oncology Clinical Trials Unit ( Site 0204) Subiaco, Western Australia | Study Coordinator |
| St. Vincent Hospital and Health Care Center, Inc ( Site 0006) Indianapolis, Indiana | Study Coordinator |
| Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0509) Toronto, Ontario | Study Coordinator |
| Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 2010) Kielce, Swietokrzyskie | Study Coordinator |
| Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Me-Oddzial Ginekologii Onkologicznej ( Sit Poznan, Wielkopolskie | Study Coordinator |
| Szpital Kliniczny im. Księżnej Anny Mazowieckiej ( Site 2009) Warsaw, Mazowieckie | Study Coordinator |
| T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Istanbul, | Study Coordinator |
| Taichung Veterans General Hospital ( Site 2602) Taichung, | Study Coordinator |
| Taipei Veterans General Hospital ( Site 2605) Taipei, | Study Coordinator |
| Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1001) Tampere, Pirkanmaa | Study Coordinator |
| Texas Oncology - Austin-USOR Texas Oncology - Austin ( Site 8003) Austin, Texas | Study Coordinator |
| Texas Oncology - Dallas-USOR Texas Oncology - Dallas (Sammons) ( Site 8005) Dallas, Texas | Study Coordinator |
| Texas Oncology - Tyler-USOR Texas Oncology - Northeast Texas ( Site 8004) Tyler, Texas | Study Coordinator |
| The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 0726) Hangzhou, Zhejiang | Study Coordinator |
| The Beatson West of Scotland Cancer Centre ( Site 2805) Glasgow, Glasgow City | Study Coordinator |
| The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0023) New York, New York | Study Coordinator |
| The Christie ( Site 2807) Manchester, England | Study Coordinator |
| The First Affiliated Hospital of Nanchang University ( Site 0729) Nanchang, Jiangxi | Study Coordinator |
| The First Affiliated Hospital of Wenzhou Medical University-Gynecology ( Site 0725) Wenzhou, Zhejiang | Study Coordinator |
| The First Hospital of Jilin University ( Site 0705) Changchun, Jilin | Study Coordinator |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C Columbus, Ohio | Study Coordinator |
| The Jikei University Hospital ( Site 1615) Minato-ku, Tokyo | Study Coordinator |
| Tianjin Medical University Cancer Institute and Hospital ( Site 0706) Tianjin, Tianjin | Study Coordinator |
| Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Frauenheilkunde und Gebur Dresden, Sachsen | Study Coordinator |
| Universitaetsklinikum Ulm ( Site 1106) Ulm, Baden-Wurttemberg | Study Coordinator |
| Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 1705) Utrecht, | Study Coordinator |
| University Medical Center Groningen ( Site 1707) Groningen, | Study Coordinator |
| University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0039) Cincinnati, Ohio | Study Coordinator |
| University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 0008) Worcester, Massachusetts | Study Coordinator |
| University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0034) Pittsburgh, Pennsylvania | Study Coordinator |
| Universitätsklinikum Bonn-Gynaecological oncology ( Site 1105) Bonn, Nordrhein-Westfalen | Study Coordinator |
| VCU Health Adult Outpatient Pavillion ( Site 0022) Richmond, Virginia | Study Coordinator |
| Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 0405) Praha, Praha 2 | Study Coordinator |
| West China Second University Hospital Sichuan University ( Site 0701) Chengdu, Sichuan | Study Coordinator |
| Westmead Hospital-Department of Gynaecological Oncology ( Site 0201) Westmead, New South Wales | Study Coordinator |
| Wuhan Union Hospital-Medical Oncology ( Site 0716) Wuhan, Hubei | Study Coordinator |
| Xiangya Hospital Central South University-Gynecology ( Site 0708) Changsha, Hunan | Study Coordinator |
| Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013) New Haven, Connecticut | Study Coordinator |
| Yaroslavl Regional Cancer Hospital-Oncology ( Site 2202) Yaroslavl, Yaroslavskaya Oblast | |
| Yunnan Province Cancer Hospital-Gynecology Department ( Site 0721) Kunming, Yunnan | Study Coordinator |
| Zhejiang Cancer Hospital-Oncology ( Site 0700) Hangzhou, Zhejiang | Study Coordinator |
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Kyle Herbert - ClinicalTrials@allovir.com
McCarty, John, M.
NCT04390113
HM20023279
Show full eligibility criteria
Hide eligibility criteria
Key Inclusion Criteria
Participants must meet all of the following criteria in order to be eligible to participate
in the study:
• Male or female ≥1 year of age.
• Had an allogeneic hematopoietic cell transplant (HCT) performed ≥21 days and ≤1 year prior to randomization.
• Myeloid engraftment confirmed, defined as an absolute neutrophil count ≥500/mm³ for 3 consecutive laboratory values obtained on different days, and platelet count >10,000/mm³ at the time of randomization.
• Diagnosed with HC based on the following criteria (all 3 criteria must be met):
• Clinical signs and/or symptoms of cystitis.
• Grade ≥3 hematuria, defined as macroscopic hematuria with visible clots.
• Viruria with ≥1 target virus (ie, BKV, JCV, AdV, CMV, EBV, and/or HHV-6).
• At least 1 identified, suitably matched posoleucel (ALVR105) cell line for infusion is available. Key Exclusion Criteria Participants who meet any of the following criteria will be excluded from participation in the study:
• Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose >0.5 mg/kg/day or equivalent).
• Therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other immunosuppressive T cell-targeted monoclonal antibodies ≤28 days before randomization.
• Evidence of active Grade >2 acute graft versus host disease (GVHD).
• Uncontrolled or progressive bacterial or fungal infections.
• Uncontrolled or progressive viral infections not targeted by posoleucel (ALVR105).
• Uncontrolled or progressive EBV-associated post-transplant lymphoproliferative disorder.
• Known or presumed pneumonia secondary to any organism that is not considered to be well-controlled by antimicrobial therapy.
• Pregnant or lactating or planning to become pregnant. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
• Male or female ≥1 year of age.
• Had an allogeneic hematopoietic cell transplant (HCT) performed ≥21 days and ≤1 year prior to randomization.
• Myeloid engraftment confirmed, defined as an absolute neutrophil count ≥500/mm³ for 3 consecutive laboratory values obtained on different days, and platelet count >10,000/mm³ at the time of randomization.
• Diagnosed with HC based on the following criteria (all 3 criteria must be met):
• Clinical signs and/or symptoms of cystitis.
• Grade ≥3 hematuria, defined as macroscopic hematuria with visible clots.
• Viruria with ≥1 target virus (ie, BKV, JCV, AdV, CMV, EBV, and/or HHV-6).
• At least 1 identified, suitably matched posoleucel (ALVR105) cell line for infusion is available. Key Exclusion Criteria Participants who meet any of the following criteria will be excluded from participation in the study:
• Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose >0.5 mg/kg/day or equivalent).
• Therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other immunosuppressive T cell-targeted monoclonal antibodies ≤28 days before randomization.
• Evidence of active Grade >2 acute graft versus host disease (GVHD).
• Uncontrolled or progressive bacterial or fungal infections.
• Uncontrolled or progressive viral infections not targeted by posoleucel (ALVR105).
• Uncontrolled or progressive EBV-associated post-transplant lymphoproliferative disorder.
• Known or presumed pneumonia secondary to any organism that is not considered to be well-controlled by antimicrobial therapy.
• Pregnant or lactating or planning to become pregnant. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Biological: Posoleucel (ALVR105), Biological: Placebo
BK Virus Infection, Hemorrhagic Cystitis
Allogeneic Hematopoietic Cell Transplant, ALVR105, Posoleucel
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 56 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AP-HP Hopital Saint-Louis Paris, | |
| Asan Medical Center Seoul, | |
| Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento Verona, | |
| Azienda Ospedaliero-Universitaria Careggi Florence, | |
| CHU de Lille - Hôpital Claude Huriez Lille, Hauts-de-France | |
| CHU de Nantes - Hôtel-Dieu Nantes, | |
| Children's Hospital of Los Angeles Glendale, California | |
| Children's Hospital of Philadelphia (CHOP) Philadelphia, Pennsylvania | |
| Children's Mercy Hospital - Kansas City Kansas City, Missouri | |
| Children's National Medical Center Washington D.C., District of Columbia | |
| Chonnam National University Hwasun Hospital Hwasun-gun, | |
| City of Hope National Medical Center Duarte, California | |
| Dana-Farber Cancer Institute Boston, Massachusetts | |
| Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Milano, | |
| Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore Rome, | |
| Fred Hutchinson Cancer Research Center Seattle, Washington | |
| Froedtert Hospital and the Medical College of Wisconsin Milwaukee, Wisconsin | |
| Great Ormond Street Hospital For Children London, | |
| HCL Centre Hospitalier Lyon Sud Pierre-Bénite, | |
| Hackensack University Medical Center Hackensack, New Jersey | |
| Hammersmith Hospital London, | |
| Hospital Clinic Barcelona Barcelona, | |
| Hospital Regional Universitario de Malaga Málaga, | |
| Hospital Universitari i Politécnic La Fe Valencia, | |
| Hospital Universitario La Paz Madrid, | |
| IRCCS Ospedale San Raffaele Milan, | |
| IUCT-Oncopole Toulouse, | |
| Istituto Clinico Humanitas Rozzano, | |
| Johns Hopkins Medicine Baltimore, Maryland | |
| Karolinska University Hospital Stockholm, | |
| MOFFITT Tampa, Florida | |
| Massachusetts General Hospital Boston, Massachusetts | |
| Northside Hospital Atlanta, Georgia | |
| Northwestern Memorial Hospital Chicago, Illinois | |
| Nottingham University Hospitals Nottingham, | |
| Ohio State University Medical Center (OSUMC) Columbus, Ohio | |
| Oregon Health & Science University Portland, Oregon | |
| Ospedale Pediatrico Bambino Gesu Rome, | |
| Pusan National University Hospital Busan, | |
| Queen Elizabeth University Hospital - Glasgow Glasgow, | |
| Roswell Park Comprehensive Cancer Center Buffalo, New York | |
| Samsung Medical Center Seoul, | |
| Seoul National University Hospital Seoul, | |
| Seoul St. Mary's Hospital, The Catholic University of Korea Seoul, | |
| Severance Hospital, Yonsei University Health System Seoul, | |
| The Royal Marsden NHS Foundation Trust Sutton, | |
| The University of Texas Southwestern Medical Center Dallas, Texas | |
| University College London Hospital London, UK | |
| University Hospitals Bristol NHS Foundation Trust Bristol, | |
| University Hospitals Cleveland Medical Center Cleveland, Ohio | |
| University of Kansas Cancer Center Kansas City, Kansas | |
| University of Miami Miami, Florida | |
| University of Minnesota Minneapolis, Minnesota | |
| University of Nebraska Medical Center Omaha, Nebraska | |
| Virginia Commonwealth University Richmond, Virginia | |
| Yale University School of Medicine - Yale Cancer Center New Haven, Connecticut |
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001
Gwaltney, Lindsey - lbgwaltney@vcu.edu
Poklepovic, Andrew, S
NCT03845166
HM20023654
drug: Avelumab,
drug: Atezolizumab
Colon, Breast, Prostate, Rectum, Other Male Genital, Urinary Bladder, Other Urinary, Kidney
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Gwaltney, Lindsey - (lbgwaltney@vcu.edu) |